

A + BOX SEQ

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b>  <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>	Attorney Docket No.	L0461/7047 (JRV)
	First Named Inventor or Application Identifier	
	Martelange	
	Express Mail Label No.	EL056827835US
	Date of Deposit	October 30, 1998

<p style="text-align: center;"><b>APPLICATION ELEMENTS</b></p> <p><i>See MPEP chapter 600 concerning utility patent application contents</i></p> <p>1. <input type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification [Total pages 67] 59 pages description 1 pages abstract 7 pages claims 50 claims</p> <p>3. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total sheets ] <input type="checkbox"/> Informal <input type="checkbox"/> Formal [Total drawings ]</p> <p>4. <input type="checkbox"/> Oath or Declaration [Total pages ] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> [Note Box 5 below] i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input type="checkbox"/> Incorporation by Reference <i>(usable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>	<p><b>ADDRESS</b> Assistant Commissioner for Patents TO: Box Patent Application Washington, DC 20231</p> <table border="1" style="width: 100%;"> <tr> <th style="text-align: center;">ACCOMPANYING APPLICATION PARTS</th> </tr> <tr> <td> <p>8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; documents(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i></p> <p>11. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity <input type="checkbox"/> Statement filed in prior Statement(s) application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p> </td> </tr> </table>	ACCOMPANYING APPLICATION PARTS	<p>8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; documents(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i></p> <p>11. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity <input type="checkbox"/> Statement filed in prior Statement(s) application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p>
ACCOMPANYING APPLICATION PARTS			
<p>8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; documents(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i></p> <p>11. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations</p> <p>12. <input type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity <input type="checkbox"/> Statement filed in prior Statement(s) application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p>			
<p>16. Other:</p>			

<b>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</b> <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input checked="" type="checkbox"/> Continuation-in-part (CIP)    of prior application No.: 09/060,706 <input type="checkbox"/> Cancel in this application claims before calculating the filing fee. <input type="checkbox"/> Amend the specification by inserting before the first line the sentence: <p style="margin-left: 40px;">This application is a <input type="checkbox"/> continuation <input type="checkbox"/> divisional of application serial no. , filed , entitled , and now .</p>					
<b>18. CORRESPONDENCE ADDRESS</b>					
Correspondence address below					
ATTORNEY'S NAME	John R. Van Amsterdam, Reg. No. 40,212				
NAME	Wolf, Greenfield & Sacks, P.C.				
ADDRESS	600 Atlantic Avenue				
CITY	Boston	STATE	MA	ZIP	02210
COUNTRY	USA	TELEPHONE	(617) 720-3500	FAX	(617) 720-2441

<b>19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED</b>	
NAME	John R. Van Amsterdam, Reg. No. 40,212
SIGNATURE	<i>John R. Van Amsterdam</i>
DATE	October 30, 1998

0013789.103098

## TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR

### Related Application

This application is a continuation-in-part of US application serial number 09/060,706,  
5 filed April 15, 1998.

### Field of the Invention

This invention relates to nucleic acid molecules and encoded polypeptides which are  
expressed preferentially in tumors, particularly in sarcomas, melanomas and carcinomas. The  
10 nucleic acid molecules and encoded polypeptides are useful in, *inter alia*, diagnostic and  
therapeutic contexts.

### Background of the Invention

The phenotypic changes which distinguish a tumor cell from its normal counterpart  
15 are often the result of one or more changes to the genome of the cell. The genes which are  
expressed in tumor cells, but not in normal counterparts, can be termed "tumor associated"  
genes. These tumor associated genes are markers for the tumor phenotype. The expression of  
tumor associated genes can also be an essential event in the process of tumorigenesis.

Typically, the host recognizes as foreign the tumor associated genes which are not  
20 expressed in normal non-tumorigenic cells. Thus, the expression of tumor associated genes  
can provoke an immune response against the tumor cells by the host. Tumor associated genes  
can also be expressed in normal cells within certain tissues without provoking an immune  
response. In such tissues, expression of the gene and/or presentation of an ordinarily  
immunologically recognizable fragment of the protein product on the cell surface may not  
25 provoke an immune response because the immune system does not "see" the cells inside these  
immunologically privileged tissues. Examples of immunologically privileged tissues include  
brain and testis

The discovery of tumor associated expression of a gene provides a means of  
identifying a cell as a tumor cell. Diagnostic compounds can be based on the tumor  
30 associated gene, and used to determine the presence and location of tumor cells. Further,  
when the tumor associated gene contributes to an aspect of the tumor phenotype (e.g.,  
unregulated growth or metastasis), the tumor associated gene can be used to provide

therapeutics such as antisense nucleic acids which can reduce or substantially eliminate expression of that gene, thereby reducing or substantially eliminating the phenotypic aspect which depends on the expression of the particular tumor associated gene.

As previously noted, the polypeptide products of tumor associated genes can be the targets for host immune surveillance and provoke selection and expansion of one or more clones of cytotoxic T lymphocytes specific for the tumor associated gene product. Examples of this phenomenon include proteins and fragments thereof encoded by the MAGE family of genes, the tyrosinase gene, the Melan-A gene, the BAGE gene, the GAGE gene, the RAGE family of genes, the PRAME gene and the brain glycogen phosphorylase gene, as are detailed below. Thus, tumor associated expression of genes suggests that such genes can encode proteins which will be recognized by the immune system as foreign and thus provide a target for tumor rejection. Such genes encode "tumor rejection antigen precursors", or TRAPs, which may be used to generate therapeutics for enhancement of the immune system response to tumors expressing such genes and proteins.

The process by which the mammalian immune system recognizes and reacts to foreign or alien materials is a complex one. An important facet of the system is the T cell response. This response requires that T cells recognize and interact with complexes of cell surface molecules, referred to as human leukocyte antigens ("HLA"), or major histocompatibility complexes ("MHCs"), and peptides. The peptides are derived from larger molecules which are processed by the cells which also present the HLA/MHC molecule. See in this regard Male et al., Advanced Immunology (J.P. Lipincott Company, 1987), especially chapters 6-10. The interaction of T cells and complexes of HLA/peptide is restricted, requiring a T cell specific for a particular combination of an HLA molecule and a peptide. If a specific T cell is not present, there is no T cell response even if its partner complex is present. Similarly, there is no response if the specific complex is absent, but the T cell is present. The mechanism is involved in the immune system's response to foreign materials, in autoimmune pathologies, and in responses to cellular abnormalities. Much work has focused on the mechanisms by which proteins are processed into the HLA binding peptides. See, in this regard, Barinaga, *Science* 257: 880, 1992; Fremont et al., *Science* 257: 919, 1992; Matsumura et al., *Science* 257: 927, 1992; Latron et al., *Science* 257: 964, 1992.

The mechanism by which T cells recognize cellular abnormalities has also been implicated in cancer. For example, in PCT application PCT/US92/04354, filed May 22, 1992,

published on November 26, 1992, and incorporated by reference, a family of genes is disclosed, which are processed into peptides which, in turn, are expressed on cell surfaces, which can lead to lysis of the tumor cells by specific CTLs. The genes are said to code for "tumor rejection antigen precursors" or "TRAP" molecules, and the peptides derived therefrom are referred to as "tumor rejection antigens" or "TRAs". See Traversari et al., *J. Exp. Med.* 176:1453-1457, 1992; van der Bruggen et al., *Science* 254: 1643,1991; De Plaen et al., *Immunogenetics* 40:360-369, 1994 and U.S. Patent No. 5,342,774 for further information on this family of genes.

In U.S. Patent No. 5,405,940, the disclosure of which is incorporated by reference, nonapeptides are taught which are presented by the HLA-A1 molecule. The reference teaches that given the known specificity of particular peptides for particular HLA molecules, one should expect a particular peptide to bind one HLA molecule, but not others. This is important, because different individuals possess different HLA phenotypes. As a result, while identification of a particular peptide as being a partner for a specific HLA molecule has diagnostic and therapeutic ramifications, these are only relevant for individuals with that particular HLA phenotype. There is a need for further work in the area, because cellular abnormalities are not restricted to one particular HLA phenotype, and targeted therapy requires some knowledge of the phenotype of the abnormal cells at issue.

In U.S. Patent Application Serial Number 008,446, filed January 22, 1993 and incorporated by reference, the fact that the MAGE-1 expression product is processed to a second TRA is disclosed. This second TRA is presented by HLA-Cw16 molecules, also known as HLA-C\*1601. The disclosure shows that a given TRAP can yield a plurality of TRAs.

In U.S. Patent Application serial no. 994,928, filed December 22, 1992, and incorporated by reference herein, tyrosinase is described as a tumor rejection antigen precursor. This reference discloses that a molecule which is produced by some normal cells (e.g., melanocytes), is processed in tumor cells to yield a tumor rejection antigen that is presented by HLA-A2 molecules.

In U.S. Patent No. 5,620,886, incorporated herein by reference in its entirety, a second TRA, not derived from tyrosinase is taught to be presented by HLA-A2 molecules. The TRA is derived from a TRAP, but is coded for by a known MAGE gene. This disclosure shows that a particular HLA molecule may present TRAs derived from different sources.

Additional TRAPs are disclosed in U.S. Patent Nos. 5,571,711, 5,610,013, 5,587,289 and 5,589,334, as well as PCT publication WO96/10577. The TRAPs are processed to tumor rejection antigens, which are presented by a variety of HLA molecules.

Presently there is a need for additional cancer antigens for development of therapeutics and diagnosis applicable to a greater number of cancer patients having various cancers.

### **Summary of the Invention**

It now has been discovered that additional genes, sdph3.10 (SAGE) and sdp3.5, unrelated to any of the foregoing TRAPs, are expressed in a tumor associated pattern in sarcoma cells. The invention provides isolated SAGE and sdp3.5 nucleic acid molecules encoding tumor associated polypeptides. The invention also provides expression vectors containing those molecules and host cells transfected with those molecules, as well as isolated polypeptides encoded by the tumor associated nucleic acid molecules (including tumor rejection antigen precursors and fragments of the isolated polypeptides). The foregoing isolated nucleic acid molecules and polypeptides can be used in the diagnosis or treatment of conditions characterized by the expression of a tumor associated gene.

According to one aspect of the invention, an isolated nucleic acid molecule is provided. The molecule hybridizes under stringent conditions to a nucleic acid having a nucleotide sequence as set forth in SEQ ID NO:38 or 43. The isolated nucleic acid molecule is a tumor associated polypeptide precursor and codes for a sdph3.10 or sdp3.5 tumor associated polypeptide. The invention further embraces nucleic acid molecules that contain deletions, additions or substitutions of the foregoing nucleic acid molecules, and nucleic acid molecules that differ from the foregoing isolated nucleic acid molecules in codon sequence to the degeneracy of the genetic code. The invention also embraces complements of the foregoing nucleic acids. In certain embodiments, the isolated nucleic acid molecule comprises the nucleic acid sequence of SEQ ID NO:1, nucleotides 119-1831 of SEQ ID NO:38, SEQ ID NO:38, SEQ ID NO:40, nucleotides 79-1659 of SEQ ID NO:43, or SEQ ID NO:43. In preferred embodiments, the isolated nucleic acid molecule comprises the coding region of the foregoing nucleic acids.

In another aspect of the invention, an isolated nucleic acid molecule comprising the nucleic acid sequence set forth as SEQ ID NO:1, SEQ ID NO:40, nucleotides 119-1831 of SEQ ID NO:38, or nucleotides 79-1659 of SEQ ID NO:43 is provided.

According to another aspect of the invention, an isolated nucleic acid molecule is provided which comprises a unique fragment of SEQ ID NO:38 or SEQ ID NO:43 that is 12 or more nucleotides in length and complements thereof. In preferred embodiments, the fragment is at least 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 30, 40, 50 or more contiguous nucleotides of the foregoing. In another embodiment, the isolated nucleic acid molecule consists of between 12 and 32 contiguous nucleotides of the foregoing. In still another embodiment, the sequence of the unique fragment includes 1, 2, 3, 4, 5, 6, or 7 contiguous nucleotides nonidentical to the sequence claimed in claim 1. Preferred fragments encode immunogenic fragments of the polypeptide encoded by the sdph3.10 or sdph3.5 nucleic acids described herein.

Methods for identifying sdph3.10 or sdph3.5 related nucleic acids, including full-length sdph3.10 or sdph3.5 cDNAs and sdph3.10 or sdph3.5 genomic DNAs, are also included in the invention. The methods include contacting a nucleic acid sample (such as a cDNA library, genomic library, genomic DNA isolate, etc.) with a nucleic acid probe or primer derived from a sdph3.10 or sdph3.5 nucleic acid such as SEQ ID NOs:1 and 38 or SEQ ID NOs:40 and 43, respectively. The nucleic acid sample and the probe or primer hybridizes to complementary nucleotide sequences of nucleic acids in the sample, if any are present, allowing detection of sdph3.10 or sdph3.5 related nucleic acids. Preferably the probe or primer is detectably labeled. The specific conditions, reagents, and the like can be selected by one of ordinary skill in the art to selectively identify sdph3.10 or sdph3.5 related nucleic acids.

According to yet another aspect of the invention, the invention involves expression vectors, and host cells transformed or transfected with such expression vectors, comprising the nucleic acid molecules described above. The expression vectors optionally include a nucleic acid molecule which codes for an HLA molecule. Of course, an HLA-encoding nucleic acid molecule can also be contained in a separate expression vector. Host cells transformed or transfected with the foregoing expression vectors are also provided.

According to another aspect of the invention, an isolated sdph3.10 or sdph3.5 polypeptide is provided which is encoded by the foregoing nucleic acid molecules. Fragments of the foregoing polypeptides also are provided. Preferably, the fragment of the isolated

polypeptide binds to a polypeptide-binding agent. In other preferred embodiments, the fragment of the isolated polypeptide binds to an antibody or a cytotoxic T lymphocyte.

The invention also provides isolated polypeptides which selectively bind a sdph3.10 or sdp3.5 protein or fragments thereof. Isolated binding polypeptides include antibodies and fragments of antibodies (e.g., Fab, F(ab)<sub>2</sub>, Fd and antibody fragments which include a CDR3 region which binds selectively to the sdph3.10 or sdp3.5 proteins of the invention). The isolated binding polypeptides include monoclonal, chimeric and humanized antibodies.

In connection with any of the isolated nucleic acids encoding a tumor associated polypeptide as described above, especially a tumor rejection antigen derived from a tumor associated polypeptide, the invention also embraces degenerate nucleic acids that differ from the isolated nucleic acid in codon sequence only due to the degeneracy of the genetic code or complements of any of the foregoing nucleic acids.

According to still another aspect of the invention, methods for diagnosing a disorder characterized by the expression of a tumor associated nucleic acid molecule or a tumor associated polypeptide are provided. The methods involve contacting a biological sample isolated from a subject with an agent that is specific for the tumor associated nucleic acid molecule or an expression product thereof. In certain embodiments, the tumor associated nucleic acid molecule hybridizes under stringent conditions to a molecule having a nucleotide sequence set forth as SEQ ID NO:38 or SEQ ID NO:43. In these certain embodiments, the tumor associated nucleic acid optionally codes for a tumor associated polypeptide. In other embodiments, the agent is a binding agent which selectively binds to a tumor associated polypeptide encoded by sdph3.10 or sdp3.5 nucleic acid molecules, such as an antibody, cytotoxic T lymphocyte, polypeptide, and the like. The methods further involve determining the interaction or binding between the agent and the nucleic acid molecule or expression product thereof as a determination of the disorder. In preferred embodiments, the agent is a nucleic acid molecule comprising a molecule having a nucleotide sequence set forth as SEQ ID NOs:38 or 43, fragments thereof, and complements thereof. In certain embodiments, the interaction between the agent and the nucleic acid molecule is determined by amplifying at least a portion of the nucleic acid molecule. In preferred embodiments, the agent which binds the tumor associated polypeptide is an antibody. In certain of the foregoing embodiments, the biological sample preferably is isolated from a non-testis tissue. In other embodiments, the biological sample preferably is isolated from a tissue excluding testis, bone marrow, bladder,

skin, uterus, ovary and sperm. In still other of the foregoing embodiments, the tumor associated nucleic acids and polypeptides are fragments of the foregoing sequences.

The recognition that peptides derived from tumor associated polypeptides may be presented by HLA molecules and recognized by CTLs permits diagnosis of certain disorders.

Thus, according to another aspect of the invention, a method for diagnosis of a disorder characterized by expression of a tumor rejection antigen derived from a tumor associated polypeptide is provided. The method involves contacting a biological sample isolated from a subject with an agent that is specific for the tumor rejection antigen derived from a tumor associated polypeptide. The method then provides for determining the interaction between the agent and the tumor rejection antigen derived from a tumor associated polypeptide as a determination of the disorder. In certain embodiments, the tumor rejection antigen derived from a tumor associated polypeptide comprises the amino acid sequence of a polypeptide encoded by SEQ ID NOs:38 or 43, or nucleic acid molecules which hybridize thereto under stringent conditions. In preferred embodiments, the tumor rejection antigen comprises between 7 and 100 consecutive amino acids (7, 8, 9, 10, 22, 12, 13, 14, 15, and so on including every integer therebetween up to 100) of the foregoing sequences. Preferably, for sdph3.10 related methods, the biological sample is isolated from non-testis tissue. For sdp3.5 related methods, the biological sample preferably is isolated from a tissue excluding testis, bone marrow, bladder, skin, uterus, ovary and sperm. In certain embodiments, the agent is an antibody.

The above-described method provides diagnosis of a disorder based on the presence of tumor associated TRAs. Another aspect of the invention provides methods for diagnosing a disorder characterized by the expression of a tumor rejection antigen derived from a tumor associated polypeptide which forms a complex with HLA molecules. The method involves contacting a biological sample isolated from a subject with an agent that binds the complex and then determining binding between the complex and the agent as a determination of the disorder. In one embodiment, the tumor rejection antigen derived from a sdph3.10 or sdp3.5 tumor associated polypeptide is a peptide comprising the amino acids of a fragment of a polypeptide encoded by SEQ ID NOs:38 or 43 or nucleic acid molecules which hybridize thereto under stringent conditions. In preferred embodiments, the tumor rejection antigen comprises between 7 and 100 consecutive amino acids of the foregoing sequences. Preferably, the biological sample is isolated non-testis tissue for sdph3.10 diagnostic methods,

or is isolated from a tissue excluding testis, bone marrow, bladder, skin, uterus, ovary and sperm for sdp3.5 diagnostic methods. In certain embodiments, the agent is an antibody. Any of the foregoing diagnostic methods can be applied sequentially over time to permit determination of the prognosis or progression of the disorder.

5 In addition to diagnosis of disorders, treatment of certain disorders is also desirable. According to another aspect of the invention, methods for treating a subject with a disorder characterized by expression of a tumor associated nucleic acid or polypeptide is provided. The method involves administering to the subject an agent which reduces the expression of the sdp3.10 or sdp3.5 tumor associated nucleic acid or polypeptide to ameliorate the  
10 disorder. The agent is administered in an effective amount. In some embodiments, the tumor associated nucleic acid or polypeptide is a nucleic acid and the agent is an antisense nucleic acid. The antisense nucleic acid preferably hybridizes to a tumor associated nucleic acid set forth as SEQ ID NOs:38 or 43, or nucleic acid molecules which hybridize thereto under stringent conditions and fragments thereof.

15 In another aspect of the invention, the tumor associated nucleic acid or polypeptide is a tumor rejection antigen and the method involves administering to a subject an amount of an agent which enriches selectively in the subject the presence of complexes of HLA and a tumor associated polypeptide or fragment thereof encoded by SEQ ID NOs:38 or 43, or nucleic acid molecules which hybridize thereto under stringent conditions, sufficient to ameliorate the  
20 disorder. In certain embodiments, the disorder is cancer.

Still other treatment methods provided by the invention involve administering to a subject in need of such treatment an amount of autologous cytolytic T cells sufficient to ameliorate the disorder, wherein the autologous cytolytic T cells are specific for complexes of an HLA molecule and a tumor rejection antigen derived from a sdp3.10 or sdp3.5 tumor  
25 associated polypeptide. Preferably the complexes are formed of HLA and the certain tumor associated peptides as described above. The methods in certain embodiments include removing an immunoreactive cell containing sample from the subject, contacting the immunoreactive cell containing sample to a host cell under conditions favoring production of cytolytic T cells against the tumor associated antigen. The cytolytic T cells are introduced to  
30 the subject in an amount effective to lyse cells which express the tumor associated antigen. Preferably the host cell is transformed or transfected with an expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter. In certain

embodiments the host cell recombinantly expresses an HLA molecule which binds the tumor associated antigen. In other embodiments the host cell endogenously expresses an HLA molecule which binds the tumor associated antigen.

According to another aspect of the invention, a composition is provided. The composition comprises an antisense nucleic acid which binds to a tumor associated nucleic acid set forth as SEQ ID NOs:38 or 43, or fragments thereof. The antisense nucleic acid reduces the expression of the tumor associated nucleic acid. The composition also includes a pharmaceutically acceptable carrier.

The invention in another aspect involves a kit for detecting the presence of the expression of a tumor associated polypeptide precursor. Such kits employ two or more of the above-described nucleic acid molecules isolated in separate containers and packaged in a single package. In one such kit, a pair of isolated nucleic acid molecules is provided, each of the pair consisting essentially of a molecule selected from the group consisting of a 12-32 nucleotide contiguous segment of SEQ ID NOs:38 or 43 and complements thereof, and wherein the contiguous segments are nonoverlapping. Preferably, the pair of isolated nucleic acid molecules is constructed and arranged to selectively amplify at least a portion of an isolated nucleic acid molecule which hybridizes under stringent conditions to a molecule selected from the group consisting of the nucleic acid sequences of SEQ ID NOs:38 or 43, nucleic acid molecules which differ from the above in codon sequence due to the degeneracy of the genetic code and complements thereof. In certain embodiments, the pair of isolated nucleic acid molecules is PCR primers. Preferably one of the primers is a contiguous segment of SEQ ID NOs:38 or 43 and another of the primers is a complement of another contiguous segment of SEQ ID NOs:38 or 43.

According to yet another aspect of the invention, methods for producing a tumor associated polypeptide are provided. The methods include providing a nucleic acid molecule comprising a sdph3.10 or sdph3.5 tumor associated nucleic acid molecule operably linked to a promoter. The tumor associated nucleic acid molecule encodes the tumor associated polypeptide or a fragment thereof, wherein the tumor associated polypeptide is selected from the group consisting of SEQ ID NO:39, SEQ ID NO:44, and fragments thereof. The methods also include expressing the nucleic acid molecule in an expression system, and isolating the tumor associated polypeptide or a fragment thereof from the expression system.

The invention in another aspect also provides pharmaceutical preparations containing the agents and/or cells of the preceding paragraphs. In one embodiment, the preparation contains a pharmaceutically effective amount of sdph3.10 or sdph3.5 polypeptides encoded by the foregoing nucleic acids, or a fragment thereof, that binds an HLA molecule along with pharmaceutically acceptable diluents, carriers or excipients. In another embodiment, the preparation contains a pharmaceutically effective amount of isolated autologous cytolytic T cells specific for complexes of an HLA molecule and a tumor rejection antigen derived from such sdph3.10 or sdph3.5 polypeptides.

According to another aspect of the invention, the use of isolated sdph3.10 or sdph3.5 polypeptides or nucleic acids, or fragments thereof, in the manufacture of a medicament is provided. Preferred fragments of the sdph3.10 or sdph3.5 molecules are described above. The use of antisense nucleic acids which bind to a tumor associated nucleic acid in the manufacture of a medicament is also provided. In certain embodiments, the medicament is an injectable medicament, an oral medicament, or an inhalable medicament.

According to another aspect of the invention, the use of isolated sdph3.10 or sdph3.5 polypeptides or nucleic acids, or fragments thereof, including antisense nucleic acids, in the manufacture of a medicament for the treatment of cancer is provided.

The invention also embraces functional variants and equivalents of all of the molecules described above.

These and other objects of the invention will be described in further detail in connection with the detailed description of the invention.

#### **Detailed Description of the Invention**

The examples which follow show the isolation of nucleic acid molecules which code for polypeptides and are expressed preferentially in tumor cells, i.e. which are tumor associated genes. It is believed that the isolated nucleic acid molecules encode sdph3.10 or sdph3.5 polypeptides because the nucleic acid molecules were initially isolated from expressed mRNA via RT-PCR amplification. Hence, one aspect of the invention is an isolated nucleic acid molecule which includes all or a fragment of the nucleotide sequence set forth in SEQ ID NO:38 or SEQ ID NO:43. This sequence does not encode a previously recognized tumor rejection antigen precursor, such as a MAGE, BAGE, GAGE, RAGE, LB33/MUM-1,

PRAME, NAG, MAGE-Xp or brain glycogen phosphorylase sequence, as will be seen by comparing them to the sequence of any of the genes described in the references.

The invention thus involves in one aspect sdph3.10 and sdp3.5 nucleic acids, encoded polypeptides, functional modifications and variants of the foregoing, useful fragments of the foregoing, as well as therapeutics and diagnostics related thereto.

The invention provides nucleic acid molecules which code for a sdph3.10 or sdp3.5 polypeptide and which hybridize under stringent conditions to a nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:38 or SEQ ID NO:43. Such nucleic acids are termed tumor associated polypeptide precursors, and may be DNA, RNA, or composed of mixed deoxyribonucleotides and ribonucleotides. The tumor associated polypeptide precursors can also incorporate synthetic non-natural nucleotides.

The invention thus encompasses other tumor associated nucleic acids, some of which may be expressed in normal tissues. A tumor associated nucleic acid or polypeptide is a nucleic acid or polypeptide expressed preferentially in cancer cells, such as tumors including sarcomas, carcinomas, etc. Various methods for determining the expression of a nucleic acid and/or a polypeptide in normal and tumor cells are known to those of skill in the art and are described further below. As used herein, tumor associated polypeptides include proteins, protein fragments, and peptides. In particular, tumor associated polypeptides include TRAPs and TRAs.

The term "stringent conditions" as used herein refers to parameters with which the art is familiar. More specifically, stringent conditions, as used herein, refers to hybridization at 65°C in hybridization buffer (3.5 x SSC, 0.02% Ficoll, 0.02% polyvinyl pyrrolidone, 0.02% Bovine Serum Albumin, 25mM NaH<sub>2</sub>PO<sub>4</sub> (pH 7), 0.5% SDS, 2mM EDTA). SSC is 0.15M sodium chloride/0.015M sodium citrate, pH 7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediaminetetracetic acid. After hybridization, the membrane upon which the nucleic acid is transferred is washed at 2 x SSC at room temperature and then at 0.1-0.5 x SSC/0.1 x SDS at temperatures up to 68°C. SSC is 0.15M sodium chloride/0.15M sodium citrate, pH 7; SDS is sodium dodecyl sulphate; and EDTA is ethylenediamine tetraacetic acid. The foregoing set of hybridization conditions is but one example of stringent hybridization conditions known to one of ordinary skill in the art.

There are other conditions, reagents, and so forth which can be used, which result in stringent hybridization (see, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et

al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York). The skilled artisan will be familiar with such conditions, and thus they are not given here. It will be understood, however, that the skilled artisan will be able to manipulate the conditions in a manner to permit the clear identification of homologs and alleles of sdph3.10 or sdph3.5 nucleic acid molecules of the invention. The skilled artisan also is familiar with the methodology for screening cells, preferably cancer cells, and libraries for expression of such molecules which then are routinely isolated, followed by isolation of the pertinent nucleic acid and sequencing. Thus sdph3.10 or sdph3.5 nucleic acids including full-length cDNAs and genomic DNAs are provided by the invention.

In general homologs and alleles typically will share at least 40% nucleotide identity and/or at least 50% amino acid identity to the coding region of tumor associated nucleic acids, in some instances will share at least 50% nucleotide identity and/or at least 65% amino acid identity and in still other instances will share at least 60% nucleotide identity and/or at least 75% amino acid identity. Preferred homologs and alleles share nucleotide and amino acid identities with SEQ ID NOs:38 or 43 and encode polypeptides of greater than 80%, more preferably greater than 90%, still more preferably greater than 95% and most preferably greater than 99% identity. The percent identity can be calculated using various, publicly available software tools developed by NCBI (Bethesda, Maryland) that can be obtained through the internet (<ftp://ncbi.nlm.nih.gov/pub/>). Exemplary tools include the BLAST system available at <http://www.ncbi.nlm.nih.gov>, which uses algorithms developed by Altschul et al. (*Nucleic Acids Res.* 25:3389-3402, 1997). Pairwise and ClustalW alignments (BLOSUM30 matrix setting) as well as Kyte-Doolittle hydropathic analysis can be obtained using the MacVector sequence analysis software (Oxford Molecular Group). Complements of the foregoing nucleic acids also are embraced by the invention.

Also provided are nucleic acid molecules which include a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:40, nucleotides 119-1831 of SEQ ID NO:38, and nucleotides 79-1659 of SEQ ID NO:43, and fragments thereof.

The nucleic acids disclosed herein are useful as probes and amplification primers for determining the expression of sdph3.10 or sdph3.5 genes according to standard hybridization procedures. The nucleic acids also can be used to express tumor associated polypeptides *in vitro* or *in vivo*, by, e.g., operably linking the nucleic acid to a promoter and transcribing and

translating the nucleic acid in an expression system. The nucleic acids also can be used to prepare fragments of such polypeptides useful for e.g., preparation of antibodies. Many other uses will be apparent to the skilled artisan.

In screening for related nucleic acids, such as nucleic acid molecules related in nucleotide sequence to sdph3.10 or sdph3.5, a Southern blot may be performed using the foregoing conditions, together with a radioactive probe (e.g. SEQ ID NO:1 or 40). After washing the membrane to which the nucleic acid is finally transferred, the membrane can be placed against x-ray film to detect the radioactive signal. In screening for the expression of tumor associated nucleic acids, Northern blot hybridizations using the foregoing conditions (see also the Examples) can be performed on samples taken from cancer patients or subjects suspected of having a condition characterized by expression of tumor associated nucleic acids. Amplification protocols such as polymerase chain reaction using primers which hybridize to the sequences presented also can be used for detection of the tumor associated nucleic acids or expression products thereof.

The invention also includes degenerate nucleic acids which include alternative codons to those present in the native materials. For example, serine residues are encoded by the codons TCA, AGT, TCC, TCG, TCT and AGC. Each of the six codons is equivalent for the purposes of encoding a serine residue. Thus, it will be apparent to one of ordinary skill in the art that any of the serine-encoding nucleotide triplets may be employed to direct the protein synthesis apparatus, *in vitro* or *in vivo*, to incorporate a serine residue. Similarly, nucleotide sequence triplets which encode other amino acid residues include, but are not limited to: CCA, CCC, CCG and CCT (proline codons); CGA, CGC, CGG, CGT, AGA and AGG (arginine codons); ACA, ACC, ACG and ACT (threonine codons); AAC and AAT (asparagine codons); and ATA, ATC and ATT (isoleucine codons). Other amino acid residues may be encoded similarly by multiple nucleotide sequences. Thus, the invention embraces degenerate nucleic acids that differ from the biologically isolated nucleic acids in codon sequence due to the degeneracy of the genetic code.

The invention also provides isolated fragments of SEQ ID NO:38, SEQ ID NO:43, or complements thereof, particularly "unique" fragments. A unique fragment is one that is a 'signature' for the larger nucleic acid. It, for example, is long enough to assure that its precise sequence is not found in molecules within the human genome outside of the tumor associated nucleic acids defined above (and human alleles). Those of ordinary skill in the art may apply

no more than routine procedures to determine if a fragment is unique within the human genome. Unique fragments, however, exclude fragments completely composed of the nucleotide sequences of any of GenBank accession numbers listed in Table VII or other previously published sequences as of the filing date of the priority documents for sequences listed in a respective priority document or the filing date of this application for sequences listed for the first time in this application which overlap the sequences of the invention.

A fragment which is completely composed of the sequence described in the foregoing GenBank deposits is one which does not include any of the nucleotides unique to the sequences of the invention. Thus, a unique fragment must contain a nucleotide sequence other than the exact sequence of those in GenBank or fragments thereof. The difference may be an addition, deletion or substitution with respect to the GenBank sequence or it may be a sequence wholly separate from the GenBank sequence.

Unique fragments can be used as probes in Southern and Northern blot assays to identify such nucleic acids, or can be used in amplification assays such as those employing PCR. As known to those skilled in the art, large probes such as 200, 250, 300 or more nucleotides are preferred for certain uses such as Southern and Northern blots, while smaller fragments will be preferred for uses such as PCR. Unique fragments also can be used to produce fusion proteins for generating antibodies or determining binding of the polypeptide fragments, or for generating immunoassay components. Likewise, unique fragments can be employed to produce nonfused fragments of the tumor associated polypeptides, useful, for example, in the preparation of antibodies, and in immunoassays. Unique fragments further can be used as antisense molecules to inhibit the expression of SAGE or sdp3.5 tumor associated nucleic acids and polypeptides, particularly for therapeutic purposes as described in greater detail below.

As will be recognized by those skilled in the art, the size of the unique fragment will depend upon its conservancy in the genetic code. Thus, some regions of SAGE or sdp3.5 sequences and complements thereof will require longer segments to be unique while others will require only short segments, typically between 12 and 32 nucleotides or more in length (e.g. 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 and 32 or more), up to the entire length of the disclosed sequence. The invention embraces each and every fragment of each sequence, beginning at the first nucleotide, the second nucleotide and so on, up to 12 nucleotides short of the end, and ending anywhere from nucleotide number 12,

13, 14 and so on for each sequence, up to the very last nucleotide (provided the sequence is unique as described above).

Many segments of the polypeptide coding region of novel tumor associated nucleic acids, or complements thereof, that are 20 or more nucleotides in length will be unique.

Those skilled in the art are well versed in methods for selecting such sequences, typically on the basis of the ability of the unique fragment to selectively distinguish the sequence of interest from other sequences in the human genome. A comparison of the sequence of the fragment to those on known databases typically is all that is necessary, although *in vitro* confirmatory hybridization and sequencing analysis may be performed.

A unique fragment can be a functional fragment. A functional fragment of a nucleic acid molecule of the invention is a fragment which retains some functional property of the larger nucleic acid molecule, such as coding for a functional polypeptide, binding to proteins, regulating transcription of operably linked nucleic acids, and the like. One of ordinary skill in the art can readily determine using the assays described herein and those well known in the art to determine whether a fragment is a functional fragment of a nucleic acid molecule using no more than routine experimentation.

For any pair of PCR primers constructed and arranged to selectively amplify, for example, a sdph3.10 nucleic acid, a sdph3.10 specific primer may be used. Such a primer is a contiguous stretch of sdph3.10 which hybridizes selectively to sdph3.10 nucleic acids. Such a specific primer would fully hybridize to a contiguous stretch of nucleotides only in sdph3.10 nucleic acids, but would hybridize at most only in part to genes that do not share the nucleotides to which the sdph3.10 specific primer binds. For efficient PCR priming and sdph3.10 nucleic acid identification, the sdph3.10 specific primer should be constructed and arranged so it does not hybridize efficiently at its 3' end to genes other than sdph3.10.

Preferably the area of non-identity is at least one to four nucleotides in length and forms the 3' end of the sdph3.10 specific primer. The kinetics of hybridization then will strongly favor hybridization at the 5' end. In this instance, 3' initiated PCR extension will occur only when both the 5' and 3' ends hybridize to the nucleic acid. Exemplary primers include SEQ ID NO:2 and SEQ ID NO:3, which are derived from SEQ ID NO:1. Other exemplary primers can differ from the above by addition or deletion of 1, 2, 3, 4, 5, or more nucleotides from the 5' end of the primer. One of ordinary skill in the art can determine with no more than routine experimentation the preferred primers for selective amplification of sdph3.10 and related

genes. Additional methods which can distinguish nucleotide sequences of substantial homology, such as ligase chain reaction ("LCR") and other methods, will be apparent to skilled artisans. The same procedures and protocols can be applied to the amplification of sdp3.5 nucleic acids.

As used herein with respect to nucleic acids, the term "isolated" means: (i) amplified *in vitro* by, for example, polymerase chain reaction (PCR); (ii) recombinantly produced by cloning; (iii) purified, as by cleavage and gel separation; or (iv) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art. An isolated nucleic acid molecule as used herein is not a naturally occurring chromosome.

The invention also provides isolated polypeptides which include translation products of SEQ ID NO:1, related sdp3.10 nucleic acids (such as cDNAs including the full-length coding region of sdp3.10, e.g. SEQ ID NO:38), SEQ ID NO:40, related sdp3.5 nucleic acids (such as cDNAs including the full-length coding region of sdp3.5, e.g. SEQ ID NO:43), and fragments of the foregoing. Such polypeptides are useful, for example, alone or as fusion proteins to generate antibodies, as a components of an immunoassay or diagnostic assay, as therapeutics, or for determining the binding specificity of HLA molecules and/or CTL clones for sdp3.10 or sdp3.5 proteins. Tumor associated polypeptides can be isolated from biological samples including tissue or cell homogenates, and can also be expressed recombinantly in a variety of prokaryotic and eukaryotic expression systems by constructing an expression vector appropriate to the expression system, introducing the expression vector into the expression system, and isolating the recombinantly expressed protein. Short polypeptides, including antigenic peptides (such as are presented by MHC molecules on the

surface of a cell for immune recognition) also can be synthesized chemically using well-established methods of peptide synthesis.

Thus, as used herein with respect to polypeptides, "isolated" means separated from its native environment and present in sufficient quantity to permit its identification or use.

Isolated, when referring to a protein or polypeptide, means, for example: (i) selectively produced by expression of a recombinant nucleic acid or (ii) purified as by chromatography or electrophoresis. Isolated proteins or polypeptides may, but need not be, substantially pure. The term "substantially pure" means that the proteins or polypeptides are essentially free of other substances with which they may be found in nature or *in vivo* systems to an extent practical and appropriate for their intended use. Substantially pure polypeptides may be produced by techniques well known in the art. Because an isolated protein may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the protein may comprise only a small percentage by weight of the preparation. The protein is nonetheless isolated in that it has been separated from the substances with which it may be associated in living systems, i.e. isolated from other proteins.

A fragment of a sdph3.10 or sdp3.5 protein, for example, generally has the features and characteristics of fragments including unique fragments as discussed above in connection with nucleic acids. As will be recognized by those skilled in the art, the size of a fragment which is unique will depend upon factors such as whether the fragment constitutes a portion of a conserved protein domain. Thus, some regions of sdph3.10 or sdp3.5 polypeptides will require longer segments to be unique while others will require only short segments, typically between 5 and 12 amino acids (e.g. 5, 6, 7, 8, 9, 10, 11 and 12 amino acids long).

Unique fragments of a polypeptide preferably are those fragments which retain a distinct functional capability of the polypeptide. Functional capabilities which can be retained in a fragment of a polypeptide include interaction with antibodies, interaction with other polypeptides or fragments thereof, selective binding of nucleic acids, and enzymatic activity. One important activity is the ability to act as a signature for identifying the polypeptide. Another is the ability to complex with HLA and to provoke in a human an immune response. A tumor rejection antigen is an example of a fragment of a tumor associated polypeptide which retains the functional capability of HLA binding and interaction with T lymphocytes. Tumor rejection antigens presented by HLA class I molecules typically are 9 amino acids in length, although peptides of 8, 9 and 10 and more amino acids also retain the capability to

interact with HLA and T lymphocytes to an extent effective to provoke a cytotoxic T lymphocyte response (see, e.g., Van den Eynde & Brichard, *Curr. Opin. Immunol.* 7:674-681, 1995; Coulie et al., *Stem Cells* 13:393-403, 1995). Similarly, tumor rejection antigens (e.g., 10 - 20 amino acids in length) can interact with HLA class II molecules and T helper lymphocytes, provoking proliferation and response of the T helper lymphocytes (see, e.g., Van den Eynde & van der Bruggen, *Curr. Opin. Immunol.* 9:684-693, 1997; Topalian et al., *J. Exp. Med.* 183:1965-1971, 1996).

Those skilled in the art are well versed in methods for selecting unique amino acid sequences, typically on the basis of the ability of the fragment to selectively distinguish the sequence of interest from non-family members. A comparison of the sequence of the fragment to those on known data bases typically is all that is necessary.

The invention embraces variants of the tumor associated polypeptides described above. As used herein, a "variant" of a tumor associated polypeptide is a polypeptide which contains one or more modifications to the primary amino acid sequence of a tumor associated polypeptide. Modifications which create a tumor associated polypeptide variant can be made to a tumor associated polypeptide 1) to reduce or eliminate an activity of the tumor associated polypeptide; 2) to enhance a property of the tumor associated polypeptide, such as protein stability in an expression system or the stability of protein-protein binding; 3) to provide a novel activity or property to a tumor associated polypeptide, such as addition of an antigenic epitope or addition of a detectable moiety; or 4) to provide equivalent or better binding to an HLA molecule. Modifications to a tumor associated polypeptide are typically made to the nucleic acid which encodes the tumor associated polypeptide, and can include deletions, point mutations, truncations, amino acid substitutions and additions of amino acids or non-amino acid moieties. Alternatively, modifications can be made directly to the polypeptide, such as by cleavage, addition of a linker molecule, addition of a detectable moiety, such as biotin, addition of a fatty acid, and the like. Modifications also embrace fusion proteins comprising all or part of the tumor associated amino acid sequences, e.g., SEQ ID NOs:39 AND 44. One of skill in the art will be familiar with methods for predicting the effect on protein conformation of a change in protein sequence, and can thus "design" a variant tumor associated polypeptide according to known methods. One example of such a method is described by Dahiyat and Mayo in *Science* 278:82-87, 1997, whereby proteins can be designed *de novo*. The method can be applied to a known protein to vary a only a portion of

the polypeptide sequence. By applying the computational methods of Dahiyat and Mayo, specific variants of a tumor associated polypeptide can be proposed and tested to determine whether the variant retains a desired conformation.

In general, variants include tumor associated polypeptides which are modified specifically to alter a feature of the polypeptide unrelated to its desired physiological activity. For example, cysteine residues can be substituted or deleted to prevent unwanted disulfide linkages. Similarly, certain amino acids can be changed to enhance expression of a tumor associated polypeptide by eliminating proteolysis by proteases in an expression system (e.g., dibasic amino acid residues in yeast expression systems in which KEX2 protease activity is present).

Mutations of a nucleic acid which encode a tumor associated polypeptide preferably preserve the amino acid reading frame of the coding sequence, and preferably do not create regions in the nucleic acid which are likely to hybridize to form secondary structures, such as hairpins or loops, which can be deleterious to expression of the variant polypeptide.

Mutations can be made by selecting an amino acid substitution, or by random mutagenesis of a selected site in a nucleic acid which encodes the polypeptide. Variant polypeptides are then expressed and tested for one or more activities to determine which mutation provides a variant polypeptide with the desired properties. Further mutations can be made to variants (or to non-variant tumor associated polypeptides) which are silent as to the amino acid sequence of the polypeptide, but which provide preferred codons for translation in a particular host. The preferred codons for translation of a nucleic acid in, e.g., *E. coli*, are well known to those of ordinary skill in the art. Still other mutations can be made to the noncoding sequences of a tumor associated gene or cDNA clone to enhance expression of the polypeptide. The activity of variants of tumor associated polypeptides can be tested by cloning the gene encoding the variant tumor associated polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the variant tumor associated polypeptide, and testing for a functional capability of the tumor associated polypeptides as disclosed herein. For example, the variant tumor associated polypeptide can be tested for reaction with autologous or allogeneic sera as disclosed in the Examples. Preparation of other variant polypeptides may favor testing of other activities, as will be known to one of ordinary skill in the art.

The skilled artisan will also realize that conservative amino acid substitutions may be made in sdph3.10 or sdph3.5 polypeptides to provide functional variants of the foregoing polypeptides, i.e., variants which retain the functional capabilities of the sdph3.10 or sdph3.5 polypeptides. As used herein, a "conservative amino acid substitution" refers to an amino acid substitution which does not alter the relative charge or size characteristics of the protein in which the amino acid substitution is made. Conservative substitutions of amino acids include substitutions made amongst amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

For example, upon determining that a peptide derived from a sdph3.10 or sdph3.5 polypeptide is presented by a MHC molecule and recognized by CTLs (e.g., as described in the Examples), one can make conservative amino acid substitutions to the amino acid sequence of the peptide, particularly at residues which are thought not to be direct contact points with the MHC molecule. For example, methods for identifying functional variants of HLA class II binding peptides are provided in a published PCT application of Strominger and Wucherpfennig (PCT/US96/03182). Peptides bearing one or more amino acid substitutions also can be tested for concordance with known HLA/MHC motifs prior to synthesis using, e.g. the computer program described by D'Amaro and Drijfhout (D'Amaro et al., *Human Immunol.* 43:13-18, 1995; Drijfhout et al., *Human Immunol.* 43:1-12, 1995) or as described below in the Examples. The substituted peptides can then be tested for binding to the MHC molecule and recognition by CTLs when bound to MHC. These variants can be tested for improved stability and are useful, *inter alia*, in vaccine compositions.

Functional variants of sdph3.10 or sdph3.5 polypeptides, i.e., variants of polypeptides which retain the function of the natural polypeptides, can be prepared according to methods for altering polypeptide sequence known to one of ordinary skill in the art such as are found in references which compile such methods, e.g. *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or *Current Protocols in Molecular Biology*, F.M. Ausubel, et al., eds., John Wiley & Sons, Inc., New York. For example, exemplary functional variants of the sdph3.10 or sdph3.5 polypeptides include conservative amino acid substitutions of polypeptides such as SEQ ID NO:39 and SEQ ID NO:44. Conservative amino-acid substitutions in the amino acid sequence of sdph3.10 or sdph3.5 polypeptides to produce functional variants of sdph3.10 or sdph3.5 polypeptides typically are made by alteration of the

nucleic acid encoding a sdph3.10 or sdph3.5 polypeptide (e.g. SEQ ID NO:38, SEQ ID NO:43). Such substitutions can be made by a variety of methods known to one of ordinary skill in the art. For example, amino acid substitutions may be made by PCR-directed mutation, site-directed mutagenesis according to the method of Kunkel (Kunkel, *Proc. Nat. Acad. Sci. U.S.A.* 82: 488-492, 1985), or by chemical synthesis of a gene encoding a sdph3.10 or sdph3.5 polypeptide. Where amino acid substitutions are made to a small unique fragment of a sdph3.10 or sdph3.5 polypeptide, such as a 9 amino acid peptide, the substitutions can be made by directly synthesizing the peptide. The activity of functional variants or fragments of sdph3.10 or sdph3.5 polypeptides can be tested by cloning the gene encoding the altered sdph3.10 or sdph3.5 polypeptide into a bacterial or mammalian expression vector, introducing the vector into an appropriate host cell, expressing the altered sdph3.10 or sdph3.5 polypeptide, and testing for a functional capability of the sdph3.10 or sdph3.5 polypeptides as disclosed herein.

As mentioned above, the invention embraces antisense oligonucleotides that selectively bind to a tumor associated gene nucleic acid molecule, including those encoding a sdph3.10 or sdph3.5 protein, to decrease transcription and/or translation of tumor associated genes. This is desirable in virtually any medical condition wherein a reduction in tumor associated gene product expression is desirable, including to reduce any aspect of a malignant cell phenotype attributable to tumor associated gene expression, such as expression of sdph3.10 or sdph3.5. Antisense molecules, in this manner, can be used to slow down or arrest such aspects of a malignant cell phenotype as found in, *inter alia*, sarcomas and carcinomas.

As used herein, the term "antisense oligonucleotide" or "antisense" describes an oligonucleotide that is an oligoribonucleotide, oligodeoxyribonucleotide, modified oligoribonucleotide, or modified oligodeoxyribonucleotide which hybridizes under physiological conditions to DNA comprising a particular gene or to an mRNA transcript of that gene and, thereby, inhibits the transcription of that gene and/or the translation of that mRNA. The antisense molecules are designed so as to interfere with transcription or translation of a target gene upon hybridization with the target gene. Those skilled in the art will recognize that the exact length of the antisense oligonucleotide and its degree of complementarity with its target will depend upon the specific target selected, including the sequence of the target and the particular bases which comprise that sequence. It is preferred that the antisense oligonucleotide be constructed and arranged so as to bind selectively with

the target under physiological conditions, i.e., to hybridize substantially more to the target sequence than to any other sequence in the target cell under physiological conditions. Based upon SEQ ID NOs:38 or 43 or upon allelic or homologous genomic and/or cDNA sequences, one of skill in the art can easily choose and synthesize any of a number of appropriate antisense molecules for use in accordance with the present invention. In order to be sufficiently selective and potent for inhibition, such antisense oligonucleotides should comprise at least 7 (Wagner et al., *Nature Biotechnology* 14:840-844, 1996) and, more preferably, at least 15 consecutive bases which are complementary to the target. Most preferably, the antisense oligonucleotides comprise a complementary sequence of 20-30 bases. Although oligonucleotides may be chosen which are antisense to any region of the gene or mRNA transcripts, in preferred embodiments the antisense oligonucleotides correspond to N-terminal or 5' upstream sites such as translation initiation, transcription initiation or promoter sites. In addition, 3'-untranslated regions may be targeted. Targeting to mRNA splicing sites has also been used in the art but may be less preferred if alternative mRNA splicing occurs. In addition, the antisense is targeted, preferably, to sites in which mRNA secondary structure is not expected (see, e.g., Sainio et al., *Cell Mol. Neurobiol.* 14(5):439-457, 1994) and at which proteins are not expected to bind. Finally, although, SEQ ID NOs:38 and 43 disclose cDNA sequences, one of ordinary skill in the art may easily derive the corresponding genomic DNA sequences. Thus, the present invention also provides for antisense oligonucleotides which are complementary to the full length cDNA and/or genomic DNA corresponding to SEQ ID NOs:38 or 43. Similarly, antisense to allelic or homologous DNAs and genomic DNAs are enabled without undue experimentation.

In one set of embodiments, the antisense oligonucleotides of the invention may be composed of "natural" deoxyribonucleotides, ribonucleotides, or any combination thereof. That is, the 5' end of one native nucleotide and the 3' end of another native nucleotide may be covalently linked, as in natural systems, via a phosphodiester internucleoside linkage. These oligonucleotides may be prepared by art recognized methods which may be carried out manually or by an automated synthesizer. They also may be produced recombinantly by vectors.

In preferred embodiments, however, the antisense oligonucleotides of the invention also may include "modified" oligonucleotides. That is, the oligonucleotides may be modified

in a number of ways which do not prevent them from hybridizing to their target but which enhance their stability or targeting or which otherwise enhance their therapeutic effectiveness.

The term "modified oligonucleotide" as used herein describes an oligonucleotide in which (1) at least two of its nucleotides are covalently linked via a synthetic internucleoside linkage (i.e., a linkage other than a phosphodiester linkage between the 5' end of one nucleotide and the 3' end of another nucleotide) and/or (2) a chemical group not normally associated with nucleic acids has been covalently attached to the oligonucleotide. Preferred synthetic internucleoside linkages are phosphorothioates, alkylphosphonates, phosphorodithioates, phosphate esters, alkylphosphonothioates, phosphoramidates, carbamates, carbonates, phosphate triesters, acetamides, peptides, and carboxymethyl esters.

The term "modified oligonucleotide" also encompasses oligonucleotides with a covalently modified base and/or sugar. For example, modified oligonucleotides include oligonucleotides having backbone sugars which are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 3' position and other than a phosphate group at the 5' position. Thus modified oligonucleotides may include a 2'-O-alkylated ribose group. In addition, modified oligonucleotides may include sugars such as arabinose instead of ribose. Modified oligonucleotides also can include base analogs such as C-5 propyne modified bases (Wagner et al., *Nature Biotechnology* 14:840- 844, 1996). The present invention, thus, contemplates pharmaceutical preparations containing modified antisense molecules that are complementary to and hybridizable with, under physiological conditions, nucleic acids encoding tumor associated proteins, together with pharmaceutically acceptable carriers.

It will also be recognized from the examples that the invention embraces the use of the sdph3.10 or sdp3.5 sequences in expression vectors, as well as to transfect host cells and cell lines, be these prokaryotic (e.g., *E. coli*), or eukaryotic (e.g., CHO cells, COS cells, yeast expression systems and recombinant baculovirus expression in insect cells). Especially useful are mammalian cells such as mouse, hamster, pig, goat, primate, etc. They can be of a wide variety of tissue types, including mast cells, fibroblasts, oocytes and lymphocytes, and they may be primary cells or cell lines. Specific examples include dendritic cells, U293 cells, peripheral blood leukocytes, bone marrow stem cells and embryonic stem cells. The expression vectors require that the pertinent sequence, i.e., those nucleic acids described *supra*, be operably linked to a promoter.

Especially preferred are nucleic acids encoding a series of epitopes, known as "polytopes". The epitopes can be arranged in sequential or overlapping fashion (*see, e.g.,* Thomson et al., *Proc. Natl. Acad. Sci. USA* 92:5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15:1280-1284, 1997), with or without the natural flanking sequences, and can be separated by unrelated linker sequences if desired. The polytope is processed to generate individual epitopes which are recognized by the immune system for generation of immune responses.

Thus, for example, peptides derived from the polypeptide having an amino acid sequence encoded by the nucleic acid of SEQ ID NOs:38 or 43, and which are presented by MHC molecules and recognized by CTL or T helper lymphocytes can be combined with peptides from other tumor rejection antigens (e.g. by preparation of hybrid nucleic acids or polypeptides) to form polytopes. Exemplary tumor associated peptide antigens that can be administered to induce or enhance an immune response are derived from tumor associated genes and encoded proteins including MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-5, MAGE-6, MAGE-7, MAGE-8, MAGE-9, MAGE-10, MAGE-11, MAGE-12, MAGE-13, GAGE-1, GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7, GAGE-8, BAGE-1, RAGE-1, LB33/MUM-1, PRAME, NAG, MAGE-Xp2 (MAGE-B2), MAGE-Xp3 (MAGE-B3), MAGE-Xp4 (MAGE-B4), tyrosinase, brain glycogen phosphorylase, Melan-A, MAGE-C1, MAGE-C2, NY-ESO-1, LAGE-1, SSX-1, SSX-2(HOM-MEL-40), SSX-1, SSX-4, SSX-5, SCP-1 and CT-7. For example, antigenic peptides characteristic of tumors include those listed in Table I below.

Table I: Exemplary Antigens

	Gene	MHC	Peptide	Position	SEQ ID NO:
25	MAGE-1	HLA-A1	EADPTGHSY	161-169	4
		HLA-Cw16	SAYGEPRKL	230-238	5
	MAGE-3	HLA-A1	EVDPIGHLY	168-176	6
		HLA-A2	FLWGPRLV	271-279	7
		HLA-B44	MEVDPIGHLY	167-176	8
30	BAGE	HLA-Cw16	AARAVFLAL	2-10	9
	GAGE-1,2	HLA-Cw16	YRPRPRRY	9-16	10

	RAGE	HLA-B7	SPSSNRIRNT	11-20	11
	GnT-V	HLA-A2	VLPDVFIRC(V)	2-10/11	12,13
	MUM-1	HLA-B44	EEKLIVVLF	exon 2/intron	14
			EEKLSVVLF (wild type)		15
5	CDK4	HLA-A2	ACDPHSGHFV	23-32	16
			ARDPHSGHFV (wild type)		17
	$\beta$ -catenin	HLA-A24	SYLDSGIHF	29-37	18
			SYLDSGIHS (wild type)		19
	Tyrosinase	HLA-A2	MLLAVLYCL	1-9	20
10		HLA-A2	YMNGTMSQV	369-377	21
		HLA-A2	YMDGTMSQV	369-377	37
		HLA-A24	AFLPWHRLF	206-214	22
		HLA-B44	SEIWRDIDF	192-200	23
		HLA-B44	YEIWRDIDF	192-200	24
15		HLA-DR4	QNILLSNAPLGQFP	56-70	25
		HLA-DR4	DYSYLQSDPDSFQD	448-462	26
	Melan-A <sup>MART-1</sup>	HLA-A2	(E)AAGIGILTV	26/27-35	27,28
		HLA-A2	ILTVILGVL	32-40	29
	gp100 <sup>Pmel117</sup>	HLA-A2	KTWGQYWQV	154-162	30
20		HLA-A2	ITDQVPFSV	209-217	31
		HLA-A2	YLEPGPVTA	280-288	32
		HLA-A2	LLDGTATLRL	457-466	33
		HLA-A2	VLYRYGSFSV	476-485	34
	DAGE	HLA-A24	LYVDSLFFL	301-309	35
25	MAGE-6	HLA-Cw16	KISGGPRISYPL	292-303	36

See, for example, PCT application publication no. WO96/10577. Other examples will be known to one of ordinary skill in the art (for example, see Coulie, *Stem Cells* 13:393-403, 1995), and can be used in the invention in a like manner as those disclosed herein. One of ordinary skill in the art can prepare polypeptides comprising one or more SAGE (sdph3.10)

and/or sdp3.5 peptides and one or more of the foregoing tumor rejection peptides, or nucleic acids encoding such polypeptides, according to standard procedures of molecular biology.

Thus polytopes are groups of two or more potentially immunogenic or immune response stimulating peptides which can be joined together in various arrangements (e.g. concatenated, overlapping). The polytope (or nucleic acid encoding the polytope) can be administered in a standard immunization protocol, e.g. to animals, to test the effectiveness of the polytope in stimulating, enhancing and/or provoking an immune response.

The peptides can be joined together directly or via the use of flanking sequences to form polytopes, and the use of polytopes as vaccines is well known in the art (see, e.g., Thomson et al., *Proc. Acad. Natl. Acad. Sci USA* 92(13):5845-5849, 1995; Gilbert et al., *Nature Biotechnol.* 15(12):1280-1284, 1997; Thomson et al., *J. Immunol.* 157(2):822-826, 1996; Tam et al., *J. Exp. Med.* 171(1):299-306, 1990). For example, Tam showed that polytopes consisting of both MHC class I and class II binding epitopes successfully generated antibody and protective immunity in a mouse model. Tam also demonstrated that polytopes comprising "strings" of epitopes are processed to yield individual epitopes which are presented by MHC molecules and recognized by CTLs. Thus polytopes containing various numbers and combinations of epitopes can be prepared and tested for recognition by CTLs and for efficacy in increasing an immune response.

It is known that tumors express a set of tumor antigens, of which only certain subsets may be expressed in the tumor of any given patient. Polytopes can be prepared which correspond to the different combination of epitopes representing the subset of tumor rejection antigens expressed in a particular patient. Polytopes also can be prepared to reflect a broader spectrum of tumor rejection antigens known to be expressed by a tumor type. Polytopes can be introduced to a patient in need of such treatment as polypeptide structures, or via the use of nucleic acid delivery systems known in the art (see, e.g., Allsopp et al., *Eur. J. Immunol.* 26(8):1951-1959, 1996). Adenovirus, pox virus, Ty-virus like particles, adeno-associated virus, plasmids, bacteria, etc. can be used in such delivery. One can test the polytope delivery systems in mouse models to determine efficacy of the delivery system. The systems also can be tested in human clinical trials.

In instances in which a human HLA class I molecule presents tumor rejection antigens derived from sdp3.10 or sdp3.5 nucleic acids, the expression vector may also include a nucleic acid sequence coding for the HLA molecule that presents any particular tumor

rejection antigen derived from these nucleic acids and polypeptides. Alternatively, the nucleic acid sequence coding for such a HLA molecule can be contained within a separate expression vector. In a situation where the vector contains both coding sequences, the single vector can be used to transfect a cell which does not normally express either one. Where the coding sequences for the tumor rejection antigen precursor and the HLA molecule which presents it are contained on separate expression vectors, the expression vectors can be cotransfected. The tumor rejection antigen precursor coding sequence may be used alone, when, e.g. the host cell already expresses a HLA molecule which presents a TRA derived from sdph3.10 or sdph3.5 TRAPs. Of course, there is no limit on the particular host cell which can be used. As the vectors which contain the two coding sequences may be used in any antigen-presenting cells if desired, and the gene for tumor rejection antigen precursor can be used in host cells which do not express a HLA molecule which presents a sdph3.10 or sdph3.5 TRA. Further, cell-free transcription systems may be used in lieu of cells.

As used herein, a "vector" may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids and phagemids. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification of cells which have or have not been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g.  $\beta$ -galactosidase, luciferase or alkaline phosphatase),

and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques (e.g., green fluorescent protein). Preferred vectors are those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

As used herein, a coding sequence and regulatory sequences are said to be "operably" joined when they are covalently linked in such a way as to place the expression or transcription of the coding sequence under the influence or control of the regulatory sequences. If it is desired that the coding sequences be translated into a functional protein, two DNA sequences are said to be operably joined if induction of a promoter in the 5' regulatory sequences results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter region to direct the transcription of the coding sequences, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a promoter region would be operably joined to a coding sequence if the promoter region were capable of effecting transcription of that DNA sequence such that the resulting transcript might be translated into the desired protein or polypeptide.

The precise nature of the regulatory sequences needed for gene expression may vary between species or cell types, but shall in general include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation respectively, such as a TATA box, capping sequence, CAAT sequence, and the like. Especially, such 5' non-transcribing regulatory sequences will include a promoter region which includes a promoter sequence for transcriptional control of the operably joined gene. Regulatory sequences may also include enhancer sequences or upstream activator sequences as desired. The vectors of the invention may optionally include 5' leader or signal sequences, 5' or 3'. The choice and design of an appropriate vector is within the ability and discretion of one of ordinary skill in the art.

Expression vectors containing all the necessary elements for expression are commercially available and known to those skilled in the art. See *Molecular Cloning: A Laboratory Manual*, J. Sambrook, et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Cells are genetically engineered by the introduction into the cells of heterologous DNA (RNA) encoding the sdph3.10 or sdph3.5 tumor associated polypeptide or fragment or variant thereof. The heterologous DNA (RNA)

is placed under operable control of transcriptional elements to permit the expression of the heterologous DNA in the host cell.

Preferred systems for mRNA expression in mammalian cells are those such as pRc/CMV (available from Invitrogen, Carlsbad, CA) that contain a selectable marker such as a gene that confers G418 resistance (which facilitates the selection of stably transfected cell lines) and the human cytomegalovirus (CMV) enhancer-promoter sequences. Additionally, suitable for expression in primate or canine cell lines is the pCEP4 vector (Invitrogen), which contains an Epstein Barr virus (EBV) origin of replication, facilitating the maintenance of plasmid as a multicopy extrachromosomal element. Another expression vector is the pEF-BOS plasmid containing the promoter of polypeptide Elongation Factor 1 $\alpha$ , which stimulates efficiently transcription *in vitro*. The plasmid is described by Mishizuma and Nagata (*Nuc. Acids Res.* 18:5322, 1990), and its use in transfection experiments is disclosed by, for example, Demoulin (*Mol. Cell. Biol.* 16:4710-4716, 1996). Still another preferred expression vector is an adenovirus, described by Stratford-Perricaudet, which is defective for E1 and E3 proteins (*J. Clin. Invest.* 90:626-630, 1992). The use of the adenovirus as an Adeno.P1A recombinant is disclosed by Warnier et al., in intradermal injection in mice for immunization against P1A (*Int. J. Cancer*, 67:303-310, 1996). Also included are bacterial systems for delivery of antigens to eukaryotic cells, such as those which utilize *Yersinia* (e.g. Starnbach and Bevan, *J. Immunol.* 153:1603, 1994) and *Listeria* (Dietrich et al., *Nature Biotechnol.* 16:181, 1998). Still other delivery and expression systems will be known to one of ordinary skill in the art.

The invention also embraces so-called expression kits, which allow the artisan to prepare a desired expression vector or vectors. Such expression kits include at least separate portions of each of the previously discussed coding sequences. Other components may be added, as desired, as long as the previously mentioned sequences, which are required, are included.

The invention also permits the construction of tumor associated gene "knock-outs" in cells and in animals, providing materials for studying certain aspects of cancer and immune system responses to cancer.

The invention as described herein has a number of uses, some of which are described elsewhere herein. First, the invention permits isolation of the tumor associated protein molecules. A variety of methodologies well-known to the skilled practitioner can be utilized

to obtain isolated tumor associated molecules. The polypeptide may be purified from cells which naturally produce the polypeptide by chromatographic means or immunological recognition. Alternatively, an expression vector may be introduced into cells to cause production of the polypeptide. In another method, mRNA transcripts may be microinjected or otherwise introduced into cells to cause production of the encoded polypeptide. Translation of mRNA in cell-free extracts such as the reticulocyte lysate system also may be used to produce polypeptide. Those skilled in the art also can readily follow known methods for isolating tumor associated polypeptides. These include, but are not limited to, immunochromatography, HPLC, size-exclusion chromatography, ion-exchange chromatography and immune-affinity chromatography.

The isolation and identification of tumor associated nucleic acids also makes it possible for the artisan to diagnose a disorder characterized by expression of tumor associated nucleic acids or polypeptides. These methods involve determining expression of one or more tumor associated nucleic acids, and/or encoded tumor associated polypeptides and/or peptides derived therefrom. In the former situation, such determinations can be carried out via any standard nucleic acid determination assay, including the polymerase chain reaction, or assaying with labeled hybridization probes. In the latter situation, such determinations can be carried out by screening patient antisera for recognition of the polypeptide or by assaying biological samples with binding partners (e.g., antibodies) for tumor associated polypeptides or complexes of antigens derived therefrom and HLA molecules.

The invention also makes it possible isolate proteins which bind to tumor associated polypeptides as disclosed herein, including antibodies and cellular binding partners of the tumor associateds. Additional uses are described further herein.

The invention also provides, in certain embodiments, "dominant negative" polypeptides derived from tumor associated polypeptides. A dominant negative polypeptide is an inactive variant of a protein, which, by interacting with the cellular machinery, displaces an active protein from its interaction with the cellular machinery or competes with the active protein, thereby reducing the effect of the active protein. For example, a dominant negative receptor which binds a ligand but does not transmit a signal in response to binding of the ligand can reduce the biological effect of expression of the ligand. Likewise, a dominant negative catalytically-inactive kinase which interacts normally with target proteins but does not phosphorylate the target proteins can reduce phosphorylation of the target proteins in

response to a cellular signal. Similarly, a dominant negative transcription factor which binds to a promoter site in the control region of a gene but does not increase gene transcription can reduce the effect of a normal transcription factor by occupying promoter binding sites without increasing transcription.

5 The end result of the expression of a dominant negative polypeptide in a cell is a reduction in function of active proteins. One of ordinary skill in the art can assess the potential for a dominant negative variant of a protein, and using standard mutagenesis techniques to create one or more dominant negative variant polypeptides. For example, one of ordinary skill in the art can modify the sequence of tumor associated polypeptides by site-specific mutagenesis, scanning mutagenesis, partial gene deletion or truncation, and the like. See, e.g., U.S. Patent No. 5,580,723 and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Second Edition, Cold Spring Harbor Laboratory Press, 1989. The skilled artisan then can test the population of mutagenized polypeptides for diminution in a selected and/or for retention of such an activity. Other similar methods for creating and testing dominant negative variants of a protein will be apparent to one of ordinary skill in the art.

10 The invention also involves agents which bind to tumor associated polypeptides encoded by sdph3.10 or sdp3.5 nucleic acid molecules ("sdph3.10 polypeptides or "sdp3.5 polypeptides"), and in certain embodiments preferably to unique fragments of the sdph3.10 or sdp3.5 polypeptides. Such binding partners can be used in screening assays to detect the presence or absence of a sdph3.10 or sdp3.5 polypeptide and in purification protocols to isolate sdph3.10 or sdp3.5 polypeptides. Likewise, such binding partners can be used to selectively target drugs, toxins or other molecules to cells which present sdph3.10 or sdp3.5 tumor associated polypeptides. In this manner, cells present in solid or non-solid tumors which express sdph3.10 or sdp3.5 tumor associated polypeptides can be treated with cytotoxic compounds. Such agents also can be used to inhibit the native activity of the tumor associated polypeptides, for example, by binding to such polypeptides.

15 The invention, therefore, also involves antibodies or fragments of antibodies having the ability to selectively bind to sdph3.10 or sdp3.5 tumor associated polypeptides, and preferably to unique fragments thereof. Antibodies include polyclonal and monoclonal antibodies, prepared according to conventional methodology.

20 The antibodies of the present invention thus are prepared by any of a variety of methods, including administering protein, fragments of protein, cells expressing the protein or

fragments thereof and the like to an animal to induce polyclonal antibodies. The production of monoclonal antibodies is according to techniques well known in the art. As detailed herein, such antibodies may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific labeling agents for imaging or to antitumor agents, including, but not limited to, methotrexate, radioiodinated compounds, toxins such as ricin, other cytostatic or cytolytic drugs, and so forth. Antibodies prepared according to the invention also preferably are specific for the TRA/HLA complexes described herein.

Significantly, as is well-known in the art, only a small portion of an antibody molecule, the paratope, is involved in the binding of the antibody to its epitope (see, in general, Clark, W.R. (1986) The Experimental Foundations of Modern Immunology Wiley & Sons, Inc., New York; Roitt, I. (1991) Essential Immunology, 7th Ed., Blackwell Scientific Publications, Oxford). The pFc' and Fc regions, for example, are effectors of the complement cascade but are not involved in antigen binding. An antibody from which the pFc' region has been enzymatically cleaved, or which has been produced without the pFc' region, designated an F(ab')<sub>2</sub> fragment, retains both of the antigen binding sites of an intact antibody. Similarly, an antibody from which the Fc region has been enzymatically cleaved, or which has been produced without the Fc region, designated an Fab fragment, retains one of the antigen binding sites of an intact antibody molecule. Proceeding further, Fab fragments consist of a covalently bound antibody light chain and a portion of the antibody heavy chain denoted Fd. The Fd fragments are the major determinant of antibody specificity (a single Fd fragment may be associated with up to ten different light chains without altering antibody specificity) and Fd fragments retain epitope-binding ability in isolation.

Within the antigen-binding portion of an antibody, as is well-known in the art, there are complementarity determining regions (CDRs), which directly interact with the epitope of the antigen, and framework regions (FRs), which maintain the tertiary structure of the paratope (see, in general, Clark, 1986; Roitt, 1991). In both the heavy chain Fd fragment and the light chain of IgG immunoglobulins, there are four framework regions (FR1 through FR4) separated respectively by three complementarity determining regions (CDR1 through CDR3). The CDRs, and in particular the CDR3 regions, and more particularly the heavy chain CDR3, are largely responsible for antibody specificity.

It is now well-established in the art that the non-CDR regions of a mammalian antibody may be replaced with similar regions of conspecific or heterospecific antibodies while retaining the epitopic specificity of the original antibody. This is most clearly manifested in the development and use of "humanized" antibodies in which non-human CDRs are covalently joined to human FR and/or Fc/pFc' regions to produce a functional antibody. Thus, for example, PCT International Publication Number WO 92/04381 teaches the production and use of humanized murine RSV antibodies in which at least a portion of the murine FR regions have been replaced by FR regions of human origin. Such antibodies, including fragments of intact antibodies with antigen-binding ability, are often referred to as "chimeric" antibodies.

Thus, as will be apparent to one of ordinary skill in the art, the present invention also provides for F(ab')<sub>2</sub>, Fab, Fv and Fd fragments; chimeric antibodies in which the Fc and/or FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric F(ab')<sub>2</sub> fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; chimeric Fab fragment antibodies in which the FR and/or CDR1 and/or CDR2 and/or light chain CDR3 regions have been replaced by homologous human or non-human sequences; and chimeric Fd fragment antibodies in which the FR and/or CDR1 and/or CDR2 regions have been replaced by homologous human or non-human sequences. The present invention also includes so-called single chain antibodies. Thus, the invention involves polypeptides of numerous size and type that bind specifically to tumor associated polypeptides including sdph3.10 or sdph3.5 polypeptides. These polypeptides may be derived also from sources other than antibody technology. For example, such polypeptide binding agents can be provided by degenerate peptide libraries which can be readily prepared in solution, in immobilized form or as phage display libraries. Combinatorial libraries also can be synthesized of peptides containing one or more amino acids. Libraries further can be synthesized of peptoids and non-peptide synthetic moieties.

Phage display can be particularly effective in identifying binding peptides useful according to the invention. Briefly, one prepares a phage library (using e.g. M13, fd, or lambda phage), displaying inserts from 4 to about 80 amino acid residues using conventional procedures. The inserts may represent a completely degenerate or biased array. One then can select phage-bearing inserts which bind to a sdph3.10 or sdph3.5 tumor associated polypeptide.

This process can be repeated through several cycles of reselection of phage that bind to a sdph3.10 or sdp3.5 polypeptide. Repeated rounds lead to enrichment of phage bearing particular sequences. DNA sequence analysis can be conducted to identify the sequences of the expressed polypeptides. The minimal linear portion of the sequence that binds to the sdph3.10 or sdp3.5 polypeptide can be determined. One can repeat the procedure using a biased library containing inserts containing part or all of the minimal linear portion plus one or more additional degenerate residues upstream or downstream thereof. Thus, the tumor associated polypeptides of the invention can be used to screen peptide libraries, including phage display libraries, to identify and select peptide binding partners of the tumor associated polypeptides of the invention. Such molecules can be used, as described, for screening assays, for diagnostic assays, for purification protocols or for targeting drugs, toxins and/or labeling agents (e.g. radioisotopes, fluorescent molecules, etc.) to cells which express tumor associated genes such as those cells which present sdph3.10 or sdp3.5 polypeptides on the cell surface. Such binding agent molecules can also be prepared to bind complexes of a sdph3.10 or sdp3.5 polypeptide and an HLA molecule by selecting the binding agent using such complexes.

A tumor associated antigen polypeptide, or a fragment thereof, also can be used to isolate their native binding partners. Isolation of such binding partners may be performed according to well-known methods. For example, isolated tumor associated antigen polypeptides can be attached to a substrate (e.g., chromatographic media, such as polystyrene beads, or a filter), and then a solution suspected of containing the binding partner may be applied to the substrate. If a binding partner which can interact with tumor associated antigen polypeptides is present in the solution, then it will bind to the substrate-bound tumor associated antigen polypeptide. The binding partner then may be isolated.

As detailed herein, the foregoing antibodies and other binding molecules may be used for example to identify tissues expressing protein or to purify protein. Antibodies also may be coupled to specific diagnostic labeling agents for imaging of cells and tissues that express tumor associated polypeptides or to therapeutically useful agents according to standard coupling procedures. Diagnostic agents include, but are not limited to, barium sulfate, iocetamic acid, iopanoic acid, ipodate calcium, diatrizoate sodium, diatrizoate meglumine, metrizamide, tyropanoate sodium and radiodiagnostics including positron emitters such as fluorine-18 and carbon-11, gamma emitters such as iodine-123, technitium-99m, iodine-131 and indium-111, nuclides for nuclear magnetic resonance such as fluorine and gadolinium.

Other diagnostic agents useful in the invention will be apparent to one of ordinary skill in the art. As used herein, "therapeutically useful agents" include any therapeutic molecule which desirably is targeted selectively to a cell expressing one of the cancer antigens disclosed herein, including antineoplastic agents, radioiodinated compounds, toxins, other cytostatic or cytolytic drugs, and so forth. Antineoplastic therapeutics are well known and include: aminoglutethimide, azathioprine, bleomycin sulfate, busulfan, carmustine, chlorambucil, cisplatin, cyclophosphamide, cyclosporine, cytarabidine, dacarbazine, dactinomycin, daunorubicin, doxorubicin, taxol, etoposide, fluorouracil, interferon- $\alpha$ , lomustine, mercaptopurine, methotrexate, mitotane, procarbazine HCl, thioguanine, vinblastine sulfate and vincristine sulfate. Additional antineoplastic agents include those disclosed in Chapter 52, Antineoplastic Agents (Paul Calabresi and Bruce A. Chabner), and the introduction thereto, pp.1202-1263, of Goodman and Gilman's "The Pharmacological Basis of Therapeutics", Eighth Edition, 1990, McGraw-Hill, Inc. (Health Professions Division). Toxins can be proteins such as, for example, pokeweed anti-viral protein, cholera toxin, pertussis toxin, ricin, gelonin, abrin, diphtheria exotoxin, or *Pseudomonas* exotoxin. Toxin moieties can also be high energy-emitting radionuclides such as cobalt-60.

The skilled artisan can determine which HLA molecule binds to tumor rejection antigens derived from sdph3.10 or sdp3.5 tumor rejection antigen precursors by, e.g., experiments utilizing antibodies to block specifically individual HLA class I molecules. For example, antibodies which bind selectively to HLA-A2 will prevent efficient presentation of TRAs specifically presented by HLA-A2. Thus, if TRAs derived from a SAGE or sdp3.5 expression product such as SEQ ID NO:39 or SEQ ID NO:44 are presented by HLA-A2, then the inclusion of anti-HLA-A2 antibodies in an *in vitro* assay will block the presentation of these TRAs. An assay for determining the nature of the HLA molecule is found in International Application No. PCT/US96/04037. Briefly, in determining the HLA molecule type, inhibition experiments were carried out where the production of tumor necrosis factor (TNF) by cytotoxic T lymphocyte (CTL) clone 263/17 was tested in the presence of monoclonal antibodies directed against HLA molecules or against CD4/CD8 accessory molecules. Four monoclonal antibodies were found to inhibit the production of TNF by CTL 263/17: monoclonal antibody W6/32, which is directed against all HLA class I molecules (Parham et al., *J. Immunol.* 123:342, 1979), antibody B1.23.2 which recognizes HLA-B and C molecules (Rebai et al., *Tissue Antigens* 22:107, 1983), antibody ME-1 which specifically

recognizes HLA-B7 (Ellis et al., *Hum. Immunol.* 5:49, 1982) and antibody B9.4.1 against CD8. No inhibition was found with antibodies directed against HLA Class II DR molecules (L243: Lampson et al., *J. Immunol.* 125:293, 1980), against HLA-A3 (GAPA 3: Berger et al., *Hybridoma* 1:87, 1982) or against CD4 (13B.8.82). The conclusion was that CTL 263/17 was of the CD8 type, and recognized an antigen presented by HLA-B7. Similar experiments using widely available anti-HLA antibodies can be performed to determine the nature of a HLA molecule which presents a SAGE (sdph3.10) or sdp3.5 antigen.

Thus isolated tumor associated polypeptide molecules when processed and presented as the TRA, or as complexes of TRA and HLA, such as HLA-A2, HLA-A26 or HLA-B7, etc. may be combined with materials such as adjuvants to produce vaccines useful in treating disorders characterized by expression of the TRAP molecule. In addition, vaccines can be prepared from cells which present the TRA/HLA complexes on their surface, such as non-proliferative cancer cells, non-proliferative transfectants, etcetera. In all cases where cells are used as a vaccine, these can be cells transfected with coding sequences for one or both of the components necessary to provoke a CTL response, or be cells which already express both molecules without the need for transfection. Vaccines also encompass naked DNA or RNA, encoding a tumor associated TRA or precursor thereof, which may be produced *in vitro* and administered via injection, particle bombardment, nasal aspiration and other methods. Vaccines of the "naked nucleic acid" type have been demonstrated to provoke an immunological response including generation of CTLs specific for the peptide encoded by the naked nucleic acid (*Science* 259:1745-1748, 1993). When "disorder" is used herein, it refers to any pathological condition where the tumor rejection antigen precursor is expressed. An example of such a disorder is cancer, sarcomas and carcinomas in particular.

As used herein, a subject is a human, non-human primate, cow, horse, pig, sheep, goat, dog, cat or rodent. In all embodiments human tumor antigens and human subjects are preferred.

Samples of tissue and/or cells for use in the various methods described herein can be obtained through standard methods such as tissue biopsy, including punch biopsy and cell scraping, and collection of blood or other bodily fluids by aspiration or other methods.

In certain embodiments of the invention, an immunoreactive cell sample is removed from a subject. By "immunoreactive cell" is meant a cell which can mature into an immune cell (such as a B cell, a helper T cell, or a cytolytic T cell) upon appropriate stimulation. Thus

immunoreactive cells include CD34<sup>+</sup> hematopoietic stem cells, immature T cells and immature B cells. When it is desired to produce cytolytic T cells which recognize a tumor associated antigen, the immunoreactive cell is contacted with a cell which expresses a tumor associated antigen under conditions favoring production, differentiation and/or selection of cytolytic T cells; the differentiation of the T cell precursor into a cytolytic T cell upon exposure to antigen is similar to clonal selection of the immune system.

Some therapeutic approaches based upon the disclosure are premised on a response by a subject's immune system, leading to lysis of antigen presenting cells, such as sarcoma, melanoma, or carcinoma cells which present one or more tumor associated antigens. One such approach is the administration of autologous CTLs specific to a tumor associated antigen/MHC complex to a subject with abnormal cells of the phenotype at issue. It is within the ability of one of ordinary skill in the art to develop such CTLs *in vitro*. An example of a method for T cell differentiation is presented in International Application number PCT/US96/05607. Generally, a sample of cells taken from a subject, such as blood cells, are contacted with a cell presenting the complex and capable of provoking CTLs to proliferate. The target cell can be a transfectant, such as a COS cell. These transfectants present the desired complex of their surface and, when combined with a CTL of interest, stimulate its proliferation. COS cells are widely available, as are other suitable host cells. Specific production of CTL clones is well known in the art. The clonally expanded autologous CTLs then are administered to the subject.

Another method for selecting antigen-specific CTL clones has recently been described (Altman et al., *Science* 274:94-96, 1996; Dumbar et al., *Curr. Biol.* 8:413-416, 1998), in which fluorogenic tetramers of MHC class I molecule/peptide complexes are used to detect specific CTL clones. Briefly, soluble MHC class I molecules are folded *in vitro* in the presence of  $\beta_2$ -microglobulin and a peptide antigen which binds the class I molecule. After purification, the MHC/peptide complex is purified and labeled with biotin. Tetramers are formed by mixing the biotinylated peptide-MHC complex with labeled avidin (e.g. phycoerythrin) at a molar ratio or 4:1. Tetramers are then contacted with a source of CTLs such as peripheral blood or lymph node. The tetramers bind CTLs which recognize the peptide antigen/MHC class I complex. Cells bound by the tetramers can be sorted by fluorescence activated cell sorting to isolate the reactive CTLs. The isolated CTLs then can be expanded *in vitro* for use as described herein.

To detail a therapeutic methodology, referred to as adoptive transfer (Greenberg, *J. Immunol.* 136(5): 1917, 1986; Riddel et al., *Science* 257: 238, 1992; Lynch et al, *Eur. J. Immunol.* 21: 1403-1410, 1991; Kast et al., *Cell* 59: 603-614, 1989), cells presenting the desired complex are combined with CTLs leading to proliferation of the CTLs specific thereto. The proliferated CTLs are then administered to a subject with a cellular abnormality which is characterized by certain of the abnormal cells presenting the particular complex. The CTLs then lyse the abnormal cells, thereby achieving the desired therapeutic goal.

The foregoing therapy assumes that at least some of the subject's abnormal cells present the relevant HLA/TRA complex. This can be determined very easily, as the art is very familiar with methods for identifying cells which present a particular HLA molecule, as well as how to identify cells expressing DNA of the pertinent sequences, in this case a tumor associated gene sequence. Once cells presenting the relevant complex are identified via the foregoing screening methodology, they can be combined with a sample from a patient, where the sample contains CTLs. If the complex presenting cells are lysed by the mixed CTL sample, then it can be assumed that a tumor associated gene derived TRA is being presented, and the subject is an appropriate candidate for the therapeutic approaches set forth *supra*.

Adoptive transfer is not the only form of therapy that is available in accordance with the invention. CTLs can also be provoked *in vivo*, using a number of approaches. One approach is the use of non-proliferative cells expressing the complex. The cells used in this approach may be those that normally express the complex, such as irradiated tumor cells or cells transfected with one or both of the genes necessary for presentation of the complex. Chen et al., *Proc. Natl. Acad. Sci. USA* 88: 110-114 (1991) exemplifies this approach, showing the use of transfected cells expressing HPV E7 peptides in a therapeutic regime. Various cell types may be used. Similarly, vectors carrying one or both of the genes of interest may be used. Viral or bacterial vectors are especially preferred. For example, nucleic acids which encode a sdph3.10 or sdp3.5 antigen may be operably linked to promoter and enhancer sequences which direct expression of the sdph3.10 or sdp3.5 antigen in certain tissues or cell types. The nucleic acid may be incorporated into an expression vector. Expression vectors may be unmodified extrachromosomal nucleic acids, plasmids or viral genomes constructed or modified to enable insertion of exogenous nucleic acids, such as those encoding sdph3.10 or sdp3.5 TRAs. Nucleic acids encoding a sdph3.10 or sdp3.5 TRA also may be inserted into a retroviral genome, thereby facilitating integration of the nucleic acid

into the genome of the target tissue or cell type. In these systems, the gene of interest is carried by a microorganism, e.g., a Vaccinia virus, retrovirus or the bacteria BCG, and the materials *de facto* "infect" host cells. The cells which result present the complex of interest, and are recognized by autologous CTLs, which then proliferate.

5 A similar effect can be achieved by combining a TRAP or a stimulatory fragment thereof with an adjuvant to facilitate incorporation into HLA presenting cells *in vivo*. The TRAP is processed to yield the peptide partner of the HLA molecule while the TRA is presented without the need for further processing. Generally, subjects can receive an intradermal injection of an effective amount of a sdph3.10 or sdph3.5 encoded TRAP, and/or  
10 TRAs derived therefrom. TRAs from sdph3.10 or sdph3.5 also can be combined with TRAs from other tumor associated polypeptides in a polytope arrangement as described above. Initial doses can be followed by booster doses, following immunization protocols standard in the art.

The invention involves the use of various materials disclosed herein to "immunize"  
15 subjects or as "vaccines". As used herein, "immunization" or "vaccination" means increasing or activating an immune response against an antigen. It does not require elimination or eradication of a condition but rather contemplates the clinically favorable enhancement of an immune response toward an antigen. Generally accepted animal models can be used for testing of immunization against cancer using a tumor associated antigen nucleic acid. For  
20 example, human cancer cells can be introduced into a mouse to create a tumor, and one or more tumor associated nucleic acids can be delivered by the methods described herein. The effect on the cancer cells (e.g., reduction of tumor size) can be assessed as a measure of the effectiveness of the tumor associated nucleic acid immunization. Of course, testing of the foregoing animal model using more conventional methods for immunization include the  
25 administration of one or more tumor associated polypeptides or peptides derived therefrom, optionally combined with one or more adjuvants and/or cytokines to boost the immune response. Methods for immunization, including formulation of a vaccine composition and selection of doses, route of administration and the schedule of administration (e.g. primary and one or more booster doses), are well known in the art. The tests also can be performed in  
30 humans, where the end point is to test for the presence of enhanced levels of circulating CTLs against cells bearing the antigen, to test for levels of circulating antibodies against the antigen, to test for the presence of cells expressing the antigen and so forth.

As part of the immunization compositions, one or more tumor associated polypeptides or stimulatory fragments thereof are administered with one or more adjuvants to induce an immune response or to increase an immune response. An adjuvant is a substance incorporated into or administered with antigen which potentiates the immune response. Adjuvants may enhance the immunological response by providing a reservoir of antigen (extracellularly or within macrophages), activating macrophages and stimulating specific sets of lymphocytes. Adjuvants of many kinds are well known in the art. Specific examples of adjuvants include monophosphoryl lipid A (MPL, SmithKline Beecham), a congener obtained after purification and acid hydrolysis of *Salmonella minnesota* Re 595 lipopolysaccharide; saponins including Q521 (SmithKline Beecham), a pure QA-21 saponin purified from *Quillja saponaria* extract; DQ521, described in PCT application WO96/33739 (SmithKline Beecham); QS-7, QS-17, QS-18, and QS-L1 (So et al., *Mol. Cells* 7:178-186, 1997); incomplete Freund's adjuvant; complete Freund's adjuvant; montanide; and various water-in-oil emulsions prepared from biodegradable oils such as squalene and/or tocopherol. Preferably, the peptides are administered mixed with a combination of DQ521/MPL. The ratio of DQ521 to MPL typically will be about 1:10 to 10:1, preferably about 1:5 to 5:1 and more preferably about 1:1. Typically for human administration, DQ521 and MPL will be present in a vaccine formulation in the range of about 1 µg to about 100 µg. Other adjuvants are known in the art and can be used in the invention (see, e.g. Goding, *Monoclonal Antibodies: Principles and Practice*, 2nd Ed., 1986). Methods for the preparation of mixtures or emulsions of peptide and adjuvant are well known to those of skill in the art of vaccination.

Other agents which stimulate the immune response of the subject can also be administered to the subject. For example, other cytokines are also useful in vaccination protocols as a result of their lymphocyte regulatory properties. Many other cytokines useful for such purposes will be known to one of ordinary skill in the art, including interleukin-12 (IL-12) which has been shown to enhance the protective effects of vaccines (see, e.g., *Science* 268: 1432-1434, 1995), GM-CSF and IL-18. Thus cytokines can be administered in conjunction with antigens and adjuvants to increase the immune response to the antigens.

There are a number of additional immune response potentiating compounds that can be used in vaccination protocols. These include costimulatory molecules provided in either protein or nucleic acid form. Such costimulatory molecules include the B7-1 and B7-2 (CD80 and CD86 respectively) molecules which are expressed on dendritic cells (DC) and interact

with the CD28 molecule expressed on the T cell. This interaction provides costimulation (signal 2) to an antigen/MHC/TCR stimulated (signal 1) T cell, increasing T cell proliferation and effector function. B7 also interacts with CTLA4 (CD152) on T cells and studies involving CTLA4 and B7 ligands indicate that the B7-CTLA4 interaction can enhance antitumor immunity and CTL proliferation (Zheng et al., *Proc. Nat'l Acad. Sci. USA* 95:6284-6289, 1998).

B7 typically is not expressed on tumor cells so they are not efficient antigen presenting cells (APCs) for T cells. Induction of B7 expression would enable the tumor cells to stimulate more efficiently CTL proliferation and effector function. A combination of B7/IL-6/IL-12 costimulation has been shown to induce IFN-gamma and a Th1 cytokine profile in the T cell population leading to further enhanced T cell activity (Gajewski et al., *J. Immunol.* 154:5637-5648, 1995). Tumor cell transfection with B7 has been discussed in relation to *in vitro* CTL expansion for adoptive transfer immunotherapy by Wang et al. (*J. Immunother.* 19:1-8, 1996). Other delivery mechanisms for the B7 molecule would include nucleic acid (naked DNA) immunization (Kim et al., *Nature Biotechnol.* 15:7:641-646, 1997) and recombinant viruses such as adeno and pox (Wendtner et al., *Gene Ther.* 4:726-735, 1997). These systems are all amenable to the construction and use of expression cassettes for the coexpression of B7 with other molecules of choice such as the antigens or fragment(s) of antigens discussed herein (including polytopes) or cytokines. These delivery systems can be used for induction of the appropriate molecules *in vitro* and for *in vivo* vaccination situations. The use of anti-CD28 antibodies to directly stimulate T cells *in vitro* and *in vivo* could also be considered.

Lymphocyte function associated antigen-3 (LFA-3) is expressed on APCs and some tumor cells and interacts with CD2 expressed on T cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Parra et al., *J. Immunol.*, 158:637-642, 1997; Fenton et al., *J. Immunother.*, 21:95-108, 1998).

Lymphocyte function associated antigen-1 (LFA-1) is expressed on leukocytes and interacts with ICAM-1 expressed on APCs and some tumor cells. This interaction induces T cell IL-2 and IFN-gamma production and can thus complement but not substitute, the B7/CD28 costimulatory interaction (Fenton et al., 1998). LFA-1 is thus a further example of a costimulatory molecule that could be provided in a vaccination protocol in the various ways discussed above for B7.

Complete CTL activation and effector function requires Th cell help through the interaction between the Th cell CD40L (CD40 ligand) molecule and the CD40 molecule expressed by DCs (Ridge et al., *Nature* 393:474, 1998; Bennett et al., *Nature* 393:478, 1998; Schoenberger et al., *Nature* 393:480, 1998). This mechanism of this costimulatory signal is likely to involve upregulation of B7 and associated IL-6/IL-12 production by the DC (APC). The CD40-CD40L interaction thus complements the signal 1 (antigen/MHC-TCR) and signal 2 (B7-CD28) interactions.

The use of anti-CD40 antibodies to stimulate DC cells directly, would be expected to enhance a response to tumor associated antigens which are normally encountered outside of an inflammatory context or are presented by non-professional APCs (tumor cells). In these situations Th help and B7 costimulation signals are not provided. This mechanism might be used in the context of antigen pulsed DC based therapies or in situations where Th epitopes have not been defined within known tumor associated antigen precursors.

The invention contemplates delivery of nucleic acids, polypeptides or peptides for vaccination. Delivery of polypeptides and peptides can be accomplished according to standard vaccination protocols which are well known in the art. In another embodiment, the delivery of nucleic acid is accomplished by *ex vivo* methods, i.e. by removing a cell from a subject, genetically engineering the cell to include a tumor associated nucleic acid, and reintroducing the engineered cell into the subject. One example of such a procedure is outlined in U.S. Patent 5,399,346 and in exhibits submitted in the file history of that patent, all of which are publicly available documents. In general, it involves introduction *in vitro* of a functional copy of a gene into a cell(s) of a subject, and returning the genetically engineered cell(s) to the subject. The functional copy of the gene is under operable control of regulatory elements which permit expression of the gene in the genetically engineered cell(s). Numerous transfection and transduction techniques as well as appropriate expression vectors are well known to those of ordinary skill in the art, some of which are described in PCT application WO95/00654. *In vivo* nucleic acid delivery using vectors such as viruses and targeted liposomes also is contemplated according to the invention.

In preferred embodiments, a virus vector for delivering a nucleic acid encoding a tumor associated polypeptide is selected from the group consisting of adenoviruses, adeno-associated viruses, poxviruses including vaccinia viruses and attenuated poxviruses, Semliki Forest virus, Venezuelan equine encephalitis virus, retroviruses, Sindbis virus, and Ty virus-

like particle. Examples of viruses and virus-like particles which have been used to deliver exogenous nucleic acids include: replication-defective adenoviruses (e.g., Xiang et al., *Virology* 219:220-227, 1996; Eloit et al., *J. Virol.* 7:5375-5381, 1997; Chengalvala et al., *Vaccine* 15:335-339, 1997), a modified retrovirus (Townsend et al., *J. Virol.* 71:3365-3374, 1997), a nonreplicating retrovirus (Irwin et al., *J. Virol.* 68:5036-5044, 1994), a replication defective Semliki Forest virus (Zhao et al., *Proc. Natl. Acad. Sci. USA* 92:3009-3013, 1995), canarypox virus and highly attenuated vaccinia virus derivative (Paoletti, *Proc. Natl. Acad. Sci. USA* 93:11349-11353, 1996), non-replicative vaccinia virus (Moss, *Proc. Natl. Acad. Sci. USA* 93:11341-11348, 1996), replicative vaccinia virus (Moss, *Dev. Biol. Stand.* 82:55-63, 1994), Venezuelan equine encephalitis virus (Davis et al., *J. Virol.* 70:3781-3787, 1996), Sindbis virus (Pugachev et al., *Virology* 212:587-594, 1995), and Ty virus-like particle (Allsopp et al., *Eur. J. Immunol* 26:1951-1959, 1996). In preferred embodiments, the virus vector is an adenovirus.

Another preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus is capable of infecting a wide range of cell types and species and can be engineered to be replication-deficient. It further has advantages, such as heat and lipid solvent stability, high transduction frequencies in cells of diverse lineages, including hematopoietic cells, and lack of superinfection inhibition thus allowing multiple series of transductions. The adeno-associated virus can integrate into human cellular DNA in a site-specific manner, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

In general, other preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral RNA into DNA with subsequent proviral integration into host cellular DNA. Adenoviruses and retroviruses have been approved for human gene therapy trials. In general, the retroviruses are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes

*in vivo*. Standard protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., "Gene Transfer and Expression, A Laboratory Manual," W.H. Freeman Co., New York (1990) and Murry, E.J. Ed. "Methods in Molecular Biology," vol. 7, Humana Press, Inc., Clifton, New Jersey (1991).

Preferably the foregoing nucleic acid delivery vectors: (1) contain exogenous genetic material that can be transcribed and translated in a mammalian cell and that can induce an immune response in a host, and (2) contain on a surface a ligand that selectively binds to a receptor on the surface of a target cell, such as a mammalian cell, and thereby gains entry to the target cell.

Various techniques may be employed for introducing nucleic acids of the invention into cells, depending on whether the nucleic acids are introduced *in vitro* or *in vivo* in a host. Such techniques include transfection of nucleic acid-CaPO<sub>4</sub> precipitates, transfection of nucleic acids associated with DEAE, transfection or infection with the foregoing viruses including the nucleic acid of interest, liposome mediated transfection, and the like. For certain uses, it is preferred to target the nucleic acid to particular cells. In such instances, a vehicle used for delivering a nucleic acid of the invention into a cell (e.g., a retrovirus, or other virus; a liposome) can have a targeting molecule attached thereto. For example, a molecule such as an antibody specific for a surface membrane protein on the target cell or a ligand for a receptor on the target cell can be bound to or incorporated within the nucleic acid delivery vehicle. Preferred antibodies include antibodies which selectively bind a tumor associated polypeptide, alone or as a complex with a MHC molecule. Especially preferred are monoclonal antibodies. Where liposomes are employed to deliver the nucleic acids of the invention, proteins which bind to a surface membrane protein associated with endocytosis may be incorporated into the liposome formulation for targeting and/or to facilitate uptake. Such proteins include capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half life, and the like. Polymeric delivery systems also have been used successfully to deliver nucleic acids into cells, as is known by those skilled in the art. Such systems even permit oral delivery of nucleic acids.

When administered, the therapeutic compositions of the present invention are administered in pharmaceutically acceptable preparations. Such preparations may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents.

The term "pharmaceutically acceptable" means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredients. The term "physiologically acceptable" refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism. The characteristics of the carrier will depend on the route of administration. Physiologically and pharmaceutically acceptable carriers include diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials which are well known in the art.

The therapeutics of the invention can be administered by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be oral, intravenous, intraperitoneal, intramuscular, intracavity, subcutaneous, or transdermal. When antibodies are used therapeutically, a preferred route of administration is by pulmonary aerosol. Techniques for preparing aerosol delivery systems containing antibodies are well known to those of skill in the art. Generally, such systems should utilize components which will not significantly impair the biological properties of the antibodies, such as the paratope binding capacity (see, for example, Sciarra and Cutie, "Aerosols," in Remington's Pharmaceutical Sciences, 18th edition, 1990, pp 1694-1712). Those of skill in the art can readily determine the various parameters and conditions for producing antibody aerosols without resort to undue experimentation. When using antisense preparations of the invention, slow intravenous administration is preferred.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may

also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.

The preparations of the invention are administered in effective amounts. An effective amount is that amount of a pharmaceutical preparation that alone, or together with further doses, stimulates the desired response. In the case of treating cancer, the desired response is inhibiting the progression of the cancer. This may involve only slowing the progression of the disease temporarily, although more preferably, it involves halting the progression of the disease permanently. In the case of stimulating an immune response, the desired response is an increase in antibodies or T lymphocytes which are specific for the immunogen(s) employed. These responses can be monitored by routine methods or can be monitored according to diagnostic methods of the invention discussed herein.

Where it is desired to stimulate an immune response using a therapeutic composition of the invention, this may involve the stimulation of a humoral antibody response resulting in an increase in antibody titer in serum, a clonal expansion of cytotoxic lymphocytes, or some other desirable immunologic response. It is believed that doses of immunogens ranging from one nanogram/kilogram to 100 milligrams/kilogram, depending upon the mode of administration, would be effective. The preferred range is believed to be between 500 nanograms and 500 micrograms per kilogram. The absolute amount will depend upon a variety of factors, including the material selected for administration, whether the administration is in single or multiple doses, and individual patient parameters including age, physical condition, size, weight, and the stage of the disease. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation.

According to another aspect of the invention, methods for diagnosing or determining the prognosis of a disorder that is characterized by expression of a SAGE (sdph3.10) and/or sdph3.5 tumor associated nucleic acid or polypeptide are provided. The methods involve contacting a biological sample isolated from a subject with an agent specific for the tumor associated nucleic acid or polypeptide to detect the presence of the tumor associated nucleic acid or polypeptide in the biological sample. Optionally, a series of tests is carried out over time to determine the subject's prognosis with respect to progression or regression of the disorder.

As used herein, "contacting" means placing the biological sample in sufficient proximity to the agent and under the appropriate conditions of, e.g., concentration, temperature, time, ionic strength, to allow the specific interaction between the agent and tumor associated nucleic acid or polypeptide that are present in the biological sample. In general, the conditions for contacting the agent with the biological sample are conditions known by those of ordinary skill in the art to facilitate a specific interaction between a molecule and its cognate (e.g., a protein and its receptor cognate, an antibody and its protein antigen cognate, a nucleic acid and its complementary sequence cognate) in a biological sample. Exemplary conditions for facilitating a specific interaction between a molecule and its cognate are described in U.S. Patent No. 5,108,921, issued to Low et al.

The biological sample can be located *in vivo* or *in vitro*. For example, the biological sample can be a tissue *in vivo* and the agent specific for the tumor associated nucleic acid or polypeptide can be used to detect the presence of such molecules in the hematopoietic tissue (e.g., for imaging portions of the tissue that express the tumor associated gene products). Alternatively, the biological sample can be located *in vitro* (e.g., a blood sample, tumor biopsy, tissue extract). In a particularly preferred embodiment, the biological sample can be a cell-containing sample, more preferably a sample containing tumor cells.

### **Examples**

#### **Example 1: Isolation of a nucleic acid specifically expressed by sarcoma cell line LB-23**

Specific cDNA fragments of sarcoma cell line LB-23 were enriched by subtraction of cDNA fragments found in normal uterus, breast, colon and heart, according to the representational difference analysis method (RDA) described for cDNA by Hubank & Schatz (*Nucl. Acids Res.* 22:5640, 1994).

Briefly, cellular cDNAs obtained by reverse transcription with an oligo-dT primer on poly-A RNA of the normal and sarcoma cell samples were digested by restriction enzyme DpnII. The DpnII fragments of each origin were ligated with the same set of adapters, divided in several groups and separately amplified by PCR. The PCR products originating from the same sample were pooled and digested again by DpnII. The DpnII fragments from the sarcoma cell line (the tester) were ligated with a new adapter set and hybridized with an excess of DpnII fragments derived from the normal tissues (the driver). The hybridization

mixture was then submitted to PCR amplification using the new adapter set. Only those DpnII fragments derived from the tester and absent in the driver were expected to be amplified exponentially because they carry primer-complementary sequences at both ends. Three cycles of subtractive hybridization and amplification were performed. The final PCR mixture products were then cloned and sequenced.

The sequencing of 106 cDNA clones yielded 42 different sequences. Twenty-seven sequences corresponded to genes recorded in databases: most of these genes are involved in cell proliferation, whereas the remaining genes are ectopically expressed differentiation genes, mitochondrial genes, oncogenes, or genes with unknown function. Fifteen cDNA clones showed no homology to any recorded gene. Among the 15 unknown sequences, one, named sdph3.10, appeared to have tumor associated expression as seen by RT-PCR. The sequence of the sdph3.10 clone was 204 bp long (SEQ ID NO:1).

#### **Example 2: Expression of gene sdph3.10 in normal tissues and tumor samples**

The expression pattern of the sdph3.10 messenger was determined by RT-PCR analysis of normal tissues and tumor samples. Two primers were selected for PCR analysis: a sense primer, sdph3.10S (5'-TGTACCTCTCAAGCAAAAT-3'; SEQ ID NO:2), located at nucleotides 7-26 of SEQ ID NO:1, and an antisense primer, sdph3.10A (5'-GTGACCCACCAGTTACAGTA-3'; SEQ ID NO:3), located at nucleotides 158-177 of SEQ ID NO:1. Total RNA of normal or tumor samples of the indicated origins were converted to cDNA. The cDNA corresponding to 50 ng of total RNA was then amplified by PCR with primers sdph3.10S and sdph3.10A with 0.625U of TaKaRa Taq polymerase for 30 cycles (94°C, 1 min; 57°C, 2 min; 72°C, 2 min) with 15' at 72°C for the final extension. The PCR using the same primers also was performed using genomic DNA as a substrate. The primers are located in different exons, as determined by the different sizes of PCR products obtained on cDNA (171 bp) or genomic DNA (approximately 750 bp).

Sdph3.10 is not expressed in a panel of normal tissues tested (Table II), with the exception of testis. Thus sdph3.10 shares an expression pattern with other tumor associated genes in that it is expressed only in immune privileged normal tissues such as testis. Among tumoral samples (Table III), sdph3.10 is frequently expressed in head and neck carcinomas (21%), bladder carcinomas (28%) and in epidermoid carcinomas of the lung (37%). Sdph 3.10 is expressed with lesser frequency in leukemia and renal tumor samples.

**Table II. Expression of gene sdph3.10 in normal tissues (RT-PCR)**

Tissue Sample	code	detection of sdph3.10
ovary	CLO7	-
kidney	BA21	-
kidney	BA4	-
adrenal glands	LB539	-
adrenal glands	LB538	-
uterus	LB1022	-
breast	LB520	-
sperm	LB568	-
skin	LB243	-
skin	LB148	-
brain	JNO9	-
testis	LB882	+++
testis	LB881	+++
heart	CLO3	-
prostate	CLO9	-
stomach	LB189	-
lung	LB264	-
lung	LB176	-
colon	LB298	-
bladder	HM83	-
liver	LB898	-
liver	CLO10	-
bone marrow	LB1039	-
PBL	LB490	-
retina	SH8	-

**Table III. Expression of gene sdph3.10 in tumors (RT-PCR)**

Sample	number	sdph3.10 positive	(%)
Cutaneous melanoma	11	0	
Primary	11	0	
Metastatic			
Uveal melanoma	3	0	
Neuroblastoma	2	0	
Bladder carcinoma	18	5	28%
Breast carcinoma	14	1	7%
Lung carcinoma NSCLC	27	7	26%
Epidermoid carcinoma	19	7	37%
Bronchiol-alveolar carcinoma	1	0	
Adenocarcinoma	7	0	
Sarcoma	9	0	
Brain tumors	6	0	
Prostate adenocarcinoma	1	0	
Head & neck carcinoma	19	4	21%
Colorectal carcinoma	19	0	
Leukemia	25	1	4%
Renal tumors	15	1	7%
Uterine tumors	5	0	
Esophagial carcinoma	7	1	14%
Mesothelioma	2	0	
Thyroid	5	0	
TOTAL Positive Positive (%)	188	20	11%

### Example 3: Isolation of a full length sdp3.10 cDNA clone.

To obtain the complete sdp3.10 cDNA, a classical cDNA library was screened with a sdp3.10 probe. The cDNA library was constructed with LB451 testis RNA in pcDNA1/Amp as described for SK29-MEL.1 RNA in U.S. Patent 5,519,117. Approximately 250,000  
5 bacteria were plated on nylon membranes. Duplicates were made and treated to denature and fix the bacterial DNA. A sdp3.10 specific probe was generated by performing RT-PCR (reverse transcription-PCR) using LB23-SARC RNA as template and sdp3.10 specific primers as described above. The 171 bp sdp3.10 PCR product was purified on a sepharose CL-6B column, then labeled using random primers, Klenow DNA polymerase and  $\alpha$ -<sup>32</sup>P-dCTP  
10 according to standard procedures. Treated duplicate nylon membranes were hybridized with the sdp3.10 specific probe (overnight incubation at 65°C), then washed in stringent conditions, and autoradiographed overnight. Positive spots were obtained. A secondary screening was performed according to standard procedures, and a bacterial clone was obtained which contained the complete sdp3.10 cDNA. The complete sdp3.10 cDNA clone was  
15 sequenced and found to be 2021 nucleotides long (SEQ ID NO:38) inclusive of the poly A tail, or about 2000 nucleotides long without the poly A tail. An open reading frame runs through the cDNA, with the first ATG at nucleotide 119 and a stop codon at nucleotide 1832. It encodes a putative protein of 571 amino-acids (SEQ ID NO:39). The gene was called SAGE, for Sarcoma AntiGen.

### Example 4: Expression of gene sdp3.5 in normal tissues and tumor samples

Among the 15 unknown sequences isolated as described in Example 1, another sequence, named sdp3.5, appeared to be overexpressed in many tumors as seen by RT-PCR. The sequence of the sdp3.5 clone was 201 bp long (SEQ ID NO:40).

25 The expression pattern of the sdp3.5 messenger was determined by RT-PCR analysis of normal tissues and tumor samples. Primers were chosen from the sequence of the sdp3.5 clone: sense primer sdp3.5S (5'-TCTCCCTGAACCTCTACTTA-3'; SEQ ID NO:41) and antisense sdp3.5A (5'-ATATCAACATTTTGACTCAT-3'; SEQ ID NO:42) correspond to nt 3-22 and the complement of nt 194-175, respectively. This PCR was performed for 30 cycles  
30 with an annealing step at 53°C starting from an amount of cDNA corresponding to 50ng of total RNA. The primers are located in different exons, as determined by the different sizes of PCR products obtained on cDNA (192 bp) or genomic DNA (approximately 1000 bp). Sdp3.5 is expressed in some normal tissues, such as uterus, bone marrow, skin, bladder,

ovary, sperm and testis (Table IV). Among tumor samples, sdp3.5 is very frequently expressed (Table V).

**Table IV. Expression of gene sdp3.5 in normal tissues (RT-PCR)**

Tissue Sample	Code	Detection of sdp3.5
ovary	CL07	+
kidney	BA21	-
kidney	BA4	-
adrenal glands	LB539	-
adrenal glands	LB538	-
uterus	LB1022	+
breast	LB520	-
sperm	LB568	++
skin	LB243	+
skin	LB148	+
brain	JN09	-
testis	LB882	+
testis	LB881	+
heart	CL03	-
prostate	CL09	-
stomach	LB189	-
lung	LB264	-
lung	LB176	-
colon	LB298	-
bladder	HM83	+
liver	LB898	-
liver	CLO10	-
bone marrow	LB1039	++
PBL	LB490	-
retina	SH8	-

Total RNA of normal samples of the indicated origins were converted to cDNA. The cDNA corresponding to 50 ng of total RNA was then amplified by PCR with primers sdp3.5S and sdp3.5A with 0.625U of TaKaRa Taq for 30 cycles (94°C for 1'; 53°C for 2'; 72°C for 2') with 15' at 72°C for the final extension.

**Table V. Expression of gene sdp3.5 in tumors (RT-PCR)**

Sample	Number	sdp3.5 positive	(%)
sarcoma	9	9	100
melanoma	25	19	76
breast carcinoma	20	11	55
renal tumors	53	37	70
bladder carcinomas	16	12	74
prostate adenocarcinoma	18	4	22
colorectal carcinoma	20	17	85
lung carcinoma	20	13	65
head and neck carcinoma	20	18	90
brain tumors	11	6	55
leukemia	12	10	84
TOTAL	224		
Positive		156	
Positive (%)			70

Total RNA of tumor samples of the indicated origins were converted to cDNA and amplified as described in Table IV.

Note: this table shows the expression of gene sdp3.5 in tumors, not an overexpression in comparison with the expression of gene sdp3.5 in normal tissues.

**Example 5: Isolation of a complete sdp3.5 cDNA**

To obtain the complete sdp3.5 cDNA, a classical cDNA library was screened with a sdp3.5 probe. The cDNA library was constructed with MZ-MEL2 RNA in pcDNA1/Amp as

described for SK29-MEL.1 RNA in U.S. Patent 5,519,117. Approximately 250,000 bacteria were plated on nylon membranes. Duplicates were made and treated to denature and fix the bacterial DNA. A sdp3.5 specific probe was generated by performing RT-PCR (reverse transcription-PCR) using LB23-SARC RNA as template and sdp3.5 specific primers as described above. The 192 bp sdp3.5 PCR product was purified on a sepharose CL-6B column, then labeled using random primers, Klenow DNA polymerase and  $\alpha$ -<sup>32</sup>P-dCTP according to standard procedures. Treated duplicate nylon membranes were hybridized with the sdp3.5 specific probe (overnight incubation at 65°C), then washed in stringent conditions, and autoradiographed overnight. Six positive spots were noticed. A secondary screening was performed according to standard procedures, and a bacterial clone was obtained which contained the complete sdp3.5 cDNA. The complete sdp3.5 cDNA clone was sequenced and found to be 2473 bp long (SEQ ID NO:43). An open reading frame runs through the cDNA, with the first ATG at nucleotide 79 and a stop codon at nucleotide 1660. It encodes a putative protein of 527 amino acids (SEQ ID NO:44), rich in leucine heptad repeats.

**Example 6: Identification of the portion of tumor associated genes encoding tumor rejection antigens.**

In a first method, available CTL clones directed against antigens presented by autologous tumor cells shown to express one or more of the tumor associated genes are screened for specificity against COS cells transfected with sdph3.10 or sdp3.5 clones and autologous HLA alleles as described by Brichard et al. (*Eur. J. Immunol.* 26:224-230, 1996). CTL recognition of sdph3.10 or sdp3.5 is determined by measuring release of TNF from the cytolytic T lymphocyte or by <sup>51</sup>Cr release assay (Herin et al., *Int. J. Cancer* 39:390-396, 1987). If a CTL clone specifically recognizes a transfected COS cell, shorter fragments of the coding sequences are prepared and tested by transfecting COS cells to identify the region of the gene that encodes the peptide recognized by the CTL. Fragments of sdph3.10 or sdp3.5 are prepared by exonuclease III digestion or other standard molecular biology methods such as PCR. Synthetic peptides are prepared and tested to confirm the exact sequence of the antigen.

Alternatively, CTL clones are generated by stimulating the peripheral blood lymphocytes (PBLs) of a patient with autologous normal cells transfected with DNA clones encoding sdph3.10 or sdp3.5 polypeptides (e.g. SEQ ID NOs:38 or 43) or with irradiated PBLs loaded with synthetic peptides corresponding to the putative proteins and matching the

consensus for the appropriate HLA class I molecule to localize the antigenic peptide within the sdph3.10 or sdp3.5 clones (see, e.g., van der Bruggen et al., *Eur. J. Immunol.* 24:3038-3043, 1994; Herman et al., *Immunogenetics* 43:377-383, 1996). Localization of one or more antigenic peptides in a protein sequence can be aided by HLA peptide binding predictions made according to established rules for binding potential (e.g., Parker et al., *J. Immunol.* 152:163, 1994; Rammensee et al., *Immunogenetics* 41:178-228, 1995). HLA binding predictions can conveniently be made using an algorithm available via the Internet on the National Institutes of Health World Wide Web site at URL <http://bimas.dcrf.nih.gov>. For example, several predicted HLA binding motifs for the sdph3.10 and sdp3.5 polypeptides (SEQ ID NOs:39 and 44) are listed in the table below:

**Table VI: Predicted HLA binding motifs in sdph3.10 and sdp3.5 polypeptides**

SEQ ID NO/amino acids	HLA molecule	Binding score ( $t_{1/2}$ disassociation)
SEQ39/AA443-451	A24	158
SEQ39/AA111-119	B_2705	2000
SEQ39/AA379-387	B_2705	600
SEQ39/AA220-228	Cw_0301	100
SEQ44/AA305-313	A_0201	133
SEQ44/AA246-254	A_0205	252
SEQ44/AA295-303	A24	360
SEQ44/AA83-91	A68.1	400
SEQ44/AA104-112	B_2702	300
SEQ44/AA358-366	B_2702	200
SEQ44/AA190-198	B_2705	10000
SEQ44/AA104-112	B_2705	10000
SEQ44/AA145-153	B_2705	6000
SEQ44/AA330-338	B_2705	3000
SEQ44/AA276-284	B_2705	2000
SEQ44/AA325-333	B7	120

Alternatively, CTL clones obtained by stimulation of lymphocytes with autologous tumor cells which express sdph3.10 or sdp3.5 are screened for specificity against COS cells

transfected with sdph3.10 or sdph3.5 cDNAs and autologous HLA alleles as described by Brichard et al. (*Eur. J. Immunol.* 26:224-230, 1996).

Optionally, shorter fragments of sdph3.10 and sdph3.5 cDNAs are generated by PCR. Shorter fragments are used to provoke TNF release or  $^{51}\text{Cr}$  release as above.

#### **Example 7: Identification of tumor associated gene encoded tumor rejection antigen peptides**

Synthetic peptides corresponding to portions of the shortest fragments of sdph3.10 and sdph3.5 which provoke TNF release are prepared. Progressively shorter peptides are synthesized to determine the optimal sdph3.10 and sdph3.5 tumor rejection antigen peptides for a given HLA molecule.

Synthetic peptides are tested for lysis of HLA expressing cells according to known procedures. For example, if the HLA which presents a peptide of interest is determined to be HLA-A2, then T2 cells can be used. T2 cells are HLA-A2<sup>+</sup> cells which have an antigen-processing defect resulting in an increased capacity to present exogenous peptides. T2 cells are mixed with a synthetic peptide corresponding to the CTL-reactive portion of sdph3.10 or sdph3.5. CTL cells are added and lysis is measured after 4 hours to determine which peptides efficiently stimulate the lysis of T2 cells bearing HLA-A2. Other HLA expressing cells are known in the art or can be prepared by transfection with specific HLA clones.

To determine the optimal size of the synthetic peptide, peptides of decreasing size are synthesized based on the sequence of the peptide determined above, by successively removing one amino acid from the amino terminal end or the carboxy terminal end of the peptide. These peptides are tested for the ability to induce cell lysis of appropriate HLA expressing cells by CTL cells in a dose response assay. Lyophilized peptides are dissolved at 20 mg/ml in DMSO, then diluted to 2 mg/ml in 10mM acetic acid and stored at -80°C. Target cells, e.g. HLA-A2<sup>+</sup> T2 cells, are labeled with  $^{51}\text{Cr}$ , as described above, for 1 hour at 37°C followed by extensive washing to remove unincorporated label. To confirm the necessity of the interaction of the peptide with the HLA, T2 cells optionally can be pretreated with an anti-HLA-A2 antibody, such as MA2.1 (Wölfel et al., *Eur. J. Immunol.* 24: 759-764, 1994), and then are incubated in 96-well microplates in the presence of various concentrations of peptides for 30 minutes at 37°C. CTLs which recognize the peptide presented by the HLA are then added in an equal volume of medium at an effector:target ratio of 30:1. Chromium-51 release is measured after 4 hours.

**Example 8: Normal cells are not lysed by CTLs which lyse cells expressing tumor associated genes**

This example describes CTL lysis experiments with various cell lines with or without incubation with the tumor associated gene derived peptides determined above. Tumor cells which express sdph3.10 or sdph3.5, normal B cells transformed with EBV (B-EBV) from the patient who is the source of the tumor cells, and normal peripheral blood lymphocytes from the same patient (PBL) are tested for lysis by CTL cells in a dose response assay. These cells are incubated with CTLs at the effector/target ratios determined to be optimal in the dose response assays detailed above, and assayed for lysis as described above. Lysis of only the sdph3.10 or sdph3.5-expressing tumor cells by the CTLs, demonstrates that B-EBV and PBL cells of the patient are not recognized by the CTLs because such cells do not normally express the tumor rejection antigen derived from sdph3.10 or sdph3.5 proteins.

It is next determined whether these cells would be lysed by CTL if pulsed with a peptide derived from sdph3.10 or sdph3.5. The peptides selected on the basis of the experiments above are tested for the ability to induce cell lysis of sdph3.10 or sdph3.5-expressing tumor cells, B-EBV cells, and non-autologous cells which express the appropriate HLA by CTL cells in a dose response assay as in previous examples. B-EBV and PBL pulsed with preferred peptides are now lysed by CTLs, as are sdph3.10 or sdph3.5-expressing tumor cells and the non-autologous cells pulsed with preferred peptides.

**Table VII: Sequence Homologies** (GenBank accession numbers)

SAGE (sdph3.10) homologies:

U89672, X90639, AF018054, AF018044, U93301, AF018053, AF018066, U93295, AF018036, L39119, AJ005168, U93302, D44443, AF033115, U52949, AF018052, L22944, U14118, D88984, U60880, AJ000542, U60877, Y10545, U89924, U60876, AF073995, X74324, AF018056, U65226, U85943, AF019886, AJ010397, Y17556, AJ001134, AF033196, AF019720, AF073473, AJ001044, AF019671, AF015523, U93294, AF046856, AC005501, AF013625, U93712, AF018071, AF045229, AF056022, AF054142, AF041461, AF019721, AF011925, U92795, AJ006789, D49729, L33810, U31958, U67221, U36623, AF048848, AF028729, U13667, U89673, AF075440, U46006, AF021811, AF054065, AF019734, U13563, AF054140, AF056702, U15425, AF054136, AF054135, AF054053, Z46845, AF053384, L38622, Z12125, AF054128, U82970, X98501, U83666, AF063304, AF030780, AF034540, AF060226, AF054049, AF056697, AF053372, AF054054, U90261, AF034793, AF030777, AF053712, AF054015, AF054143, AF054131, AF054125, AF034805, AF034539, AF030779, AF018055, AF053381, U89574, AF026953, AF054060, AF054035, Z77249, U58669, U37222, AF042783, AF030774, Y16911, AF054086, X96611, X96612, AF054122, X85119, U06752, AF030773, X85120, X85121, X85123, X85118,

AF054039, AF054033, L08948, L08952, U64448, U22492, Y14971, AF053374, L40600,  
AF002993, U49757, AF026198, L01095, X98450, Z73924, U50426, D82082, Z73917,  
U35433, U93298, X98613, Y16912, L19898, U33955, AF045381, X98409, U31738,  
AF054078, Y13934, X99439, AA608952, AA928800, AI085076, W86797, AA496651,  
5 AA514191, R82515, AA514190, F20468, F20464, F20486, F20192, F20456, F20187,  
F20374, F20206, F20380, F20407, F20389, F20446, F20457, F20451, F20404, F20485,  
F20449, F20193, F20181, F20460, F20509, F20484, F20508, F20430, F20490, F20453,  
F20208, F20194, F20495, F20198, F20497, F20201, F20487, F20455, F20205, F20214,  
F20189, F20182, F20376, F20459, F20450, F20197, F20471, F20499, F20373, F20209,  
10 F20212, F20472, F20494, F20461, F20188, F20448, F20502, F20377, F20412, F20443,  
F20410, F20488, F20191, F20431, F20180, F20408, F20489, F20203, F20500, F20470,  
F20406, F20388, F20386, F20213, F21475, F20387, F21480, F20199, F20379, F20190,  
F20381, F20378, F20429, F20384, F20503, F20382, F20411, F20416, F20215, F20458,  
F20419, F20216, F20210, F20418, F20385, F20196, F20204, F20195, F22435, F20465,  
15 F20447, F20462, F20507, F20375, F20218, F20383, F20505, F20202, F20390, F20454,  
F20498, F20207, F20463, F20445, F20501, F20220, F21491, F20405, AA996393, F20219,  
AF037645, AA376143, AF074090, W87308, H43402, H30783, R82572, H83744, W01374,  
W01402, AA280761, AA089904, F20493, W91597, AA189462, AA203802, AA170068,  
U24210, AA155054, W91680, W91767, AI173151, AA791964, AA980070, AA110295,  
20 AF027363, AF064731, AF062411, AF064739, U83004, AA514079, U19683, W43399,  
AI110278, AU008656, AA898685, AU009621, AU008677, AU007296, AA125726,  
AU010430, AU009475, AU009482, AI137061, AA803678, AU007939, AU012580,  
AU012951, AU012816, AA542562, C45885, D67685, T18032.

sdp3.5 homologies:

D44443, AF018054, AF018036, U14118, U52949, U93301, U60880, U89672, AF018044,  
D88984, AF033115, AF018053, X74324, L22944, AJ000542, X90639, L39119, U60877,  
AF018052, AF018066, AJ005168, U60876, U89924, AF073995, U93302, U93295, Y10545,  
30 AF018056, U65226, AF056365, U85943, AF019886, Y17556, AJ010397, AJ001134,  
AF073473, AF019720, U93294, AF033196, AF019671, AF015523, AJ001044, AF056364,  
AC005501, AF046856, AF018071, U93712, AF013625, AF045229, AF054142, AF041461,  
AF019721, AF056022, U92795, AF011925, AJ006789, D49729, L33810, X19598,  
AF056366, AF056368, AF056367, U67221, U36623, AF028729, U13667, AF075440,  
35 AF06006, AF054065, AF021811, AF019734, U13563, U89673, AF048848, AF054140,  
AF056702, U15425, AF054136, AF054135, AF054053, Z46845, Z12125, L38622,  
AF053384, X98501, U83666, AF054128, U82970, AF054131, AF060226, AF063304,  
AF030780, AF034540, AF054049, AF053372, AF056697, AF054143, AF053712, U90261,  
AF034793, AF030777, AF054054, AF054015, AF034539, AF030779, AF034805,  
40 AF018055, AF054125, AF054060, U89574, AF053381, AF054035, AC003658, X96612,  
U37222, AF042783, AF030774, Y16911, X96611, U58669, AF054086, AF054122, X85120,  
Z33042, X85121, X85123, X85118, AF054110, AF054033, AF054039, AF054031, U41023,  
X85119, AF030773, U06752, AJ007973, AF053374, AF023460, M97764, U64448, U22492,  
Z68223, L40600, U67952, U64849, AC005617, X92804, AF045381, U49757, Z21512,  
45 U93298, Y16912, X56584, AC004104, AC004891, Z54336, S62834, AF054078, AI052728,  
AA807217, AA213817, AA825936, AA756999, AA907054, AA609375, AA213896,  
R82515, F20412, F20206, F20376, F20497, F20456, F20443, F20460, F20188, F20377,  
F20446, F20212, F20380, F20192, F20453, F20487, F20182, AA514191, F20490, F20508,  
F20194, F20484, F20214, F20448, F20181, F20201, F20461, F20198, F20208, F20471,

F20430, F20374, F20450, F20495, F20485, F20464, F20499, F20205, F20509, F20189,  
F20193, F20486, F20455, F20502, F20404, F20468, AA514190, F20459, F20197, F20457,  
F20407, F20187, F20494, F20472, F20373, F20209, F20389, F20451, F20449, F20410,  
F20488, F20489, F20191, F20431, F20408, F20180, F20203, F20470, F20406, F20388,  
F20386, F20500, F20213, F20379, F20199, F21480, F20387, F20190, F21475, F20384,  
F20503, F20381, F20378, F20429, F20416, F20215, F20458, F20419, F20216, F20210,  
F20418, F20382, F20385, F20411, F20196, F20204, F22435, F20195, F20507, F20462,  
F20447, F20465, F20375, F20207, F20463, F20445, F20505, F20202, F20390, F20454,  
F20498, F20218, F20383, F20501, F20220, F21491, F20405, AA996393, F20219,  
AF037645, AF074090, H30783, H43402, R82572, T85999, T95201, AA765033, H11252,  
T08028, T18866, R00936, AI077982, N75456, W94676, AA436899, AA728973, AA166988,  
AA424248, AA860409, AA936238, AI187706, AA909429, AA948413, AI050788,  
AI192259, T18857, T97605, W80475, AI002684, R71480, AA428287, AA442255,  
AA442256, F09233, AA788910, AA831784, AA933632, T98507, R43330, H22100, F20493,  
AA479924, AA400080, N72766, AA545060, AA420348, AA254513, W91597, U24210,  
W91680, W91767, AA543234, AA615729, AA032981, AA914248, AA120644, AA066421,  
AA756108, W82714, AI019528, W14257, AA407292, W11518, AA444251, AA072736,  
AA111345, AI049160, AA895702, AA407127, W99877, AA111456, W11611, AA500566,  
AA185493, W81972, AA073118, AA516678, AA855403, AA959167, AA260133,  
AF027363, AF064731, AF062411, AF064739, U83004, U19683, AA514079, AI211282,  
AA850085, AI030030, AA999178, AA695049, AA550648, AA415100, AI101778,  
AA735448, D37132, AA866472, D67847, C23390, C60145, C63966, C63790, AA660375,  
AI187590, U44990, AA917226, AA899456, AA980032, T41951, AU029442, D36797,  
C23030, AI172014, D37722, AA991037, AI071518, AA140968, D27835.

The terms and expressions which have been employed are used as terms of description  
and not of limitation, and there is no intention in the use of such terms and expressions of  
excluding any equivalents of the features shown and described or portions thereof, it being  
recognized that various modifications are possible within the scope of the invention.

All of the references described herein are incorporated by reference.

What is claimed is:

**CLAIMS**

1. An isolated nucleic acid molecule selected from the group consisting of:
  - (a) nucleic acid molecules which hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43, and which code for a sarcoma associated gene product,
  - (b) deletions, additions and substitutions of the nucleic acid molecules of (a), which code for a sarcoma associated gene product,
  - (c) nucleic acid molecules that differ from the nucleic acid molecules of (a) or (b) in codon sequence due to the degeneracy of the genetic code, and
  - (d) complements of (a), (b) and (c).
2. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:1.
3. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as nucleotides 119-1831 of SEQ ID NO:38.
4. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:38.
5. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:40.
6. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as nucleotides 79-1659 of SEQ ID NO:43.
7. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule comprises the nucleic acid sequence set forth as SEQ ID NO:43.

8. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:40, nucleotides 119-1831 of SEQ ID NO:38, and nucleotides 79-1659 of SEQ ID NO:43.

9. An isolated nucleic acid molecule selected from the group consisting of:

(a) a unique fragment of the nucleotide sequence set forth as nucleotides 1-1997 of SEQ ID NO:38 between 12 and 1996 nucleotides in length,

(b) a unique fragment of the nucleotide sequence set forth as nucleotides 1-2442 of SEQ ID NO:43 between 12 and 2441 nucleotides in length and

(c) complements of (a) and (b).

10. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 14 contiguous nucleotides.

11. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 16 contiguous nucleotides.

12. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 18 contiguous nucleotides.

13. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 20 contiguous nucleotides.

14. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 22 contiguous nucleotides.

15. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 25 contiguous nucleotides.

16. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is at least 30 contiguous nucleotides.

17. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is between 12 and 32 contiguous nucleotides.

18. An expression vector comprising the isolated nucleic acid molecule of any of claims 1-17 operably linked to a promoter.

19. A host cell transformed or transfected with the expression vector of claim 18.

20. An isolated polypeptide encoded by the isolated nucleic acid molecule of any of claims 1-8.

21. An isolated polypeptide comprising a fragment of the polypeptide of claim 20 at least 9 amino acids in length.

22. The isolated polypeptide of claim 21, wherein the fragment binds to a polypeptide-binding agent.

23. The isolated polypeptide of claim 22, wherein the fragment binds to an antibody or a cytotoxic T lymphocyte.

24. An isolated polypeptide which selectively binds a protein encoded by the isolated nucleic acid molecule of any of claims 1-8.

25. The isolated polypeptide of claim 24, wherein the isolated polypeptide is an Fab or F(ab)<sub>2</sub> fragment of an antibody.

26. The isolated polypeptide of claim 24, wherein the isolated polypeptide is a fragment of an antibody, the fragment including a CDR3 region selective for the protein.

27. The isolated polypeptide of claim 24, wherein the isolated polypeptide is selected from the group consisting of monoclonal antibodies, humanized antibodies and chimeric antibodies.

28. A method for diagnosing a disorder characterized by expression of a tumor associated nucleic acid molecule, comprising:

contacting a biological sample isolated from a subject with an agent that is specific for the tumor associated nucleic acid molecule, wherein the tumor associated nucleic acid molecule hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43, and

determining the interaction between the agent and the tumor associated nucleic acid molecule as a determination of the disorder.

29. The method of claim 28 wherein the agent is a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43, fragments thereof, and complements thereof.

30. The method of claim 28, wherein the agent comprises a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:38, fragments thereof, and complements thereof.

31. The method of claim 30, wherein the biological sample is isolated from a non-testis tissue.

32. The method of claim 28, wherein the agent comprises a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:43, fragments thereof, and complements thereof.

33. The method of claim 32, wherein the biological sample is isolated from a tissue excluding tissues selected from the group consisting of testis, bone marrow, bladder, skin, uterus, ovary and sperm.

34. The method of claim 28 wherein the interaction is determined by amplifying at least a portion of the nucleic acid molecule.

35. A method for diagnosing a disorder characterized by expression of a tumor associated polypeptide, comprising:

contacting a biological sample isolated from a subject with an agent that binds the tumor associated polypeptide as claimed in claim 20, and

determining binding between the tumor associated polypeptide and the agent as a determinant of the disorder.

36. The method of claim 35, wherein the tumor associated polypeptide is a polypeptide encoded by a nucleotide sequence selected from the group consisting of SEQ ID NO:38, SEQ ID NO:43, and fragments thereof.

37. The method of claim 35, wherein the agent is an antibody or fragment thereof.

38. A method for treating a subject with a disorder characterized by expression of a tumor associated nucleic acid as claimed in claim 1, comprising administering to the subject an effective amount of an agent which reduces the expression of the tumor associated nucleic acid, sufficient to ameliorate the disorder.

39. The method of claim 38 wherein the agent which reduces the expression of the tumor associated nucleic acid is an antisense nucleic acid which hybridizes to the tumor associated nucleic acid.

40. A composition comprising:  
an antisense nucleic acid which binds to a tumor associated nucleic acid which hybridizes under stringent conditions to a nucleic acid molecule having a nucleotide sequence selected from the group consisting of SEQ ID NO:38 and SEQ ID NO:43, and reduces the expression of the tumor associated nucleic acid, and  
a pharmaceutically acceptable carrier.

41. A kit for detecting the presence of the expression of a tumor associated polypeptide precursor comprising a first isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of SEQ ID NO:38, and a second isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of the complement of SEQ ID NO:38, wherein the contiguous segments are nonoverlapping.

42. The kit of claim 41, wherein the first and the second isolated nucleic acid molecules are constructed and arranged to selectively amplify at least a portion of an isolated nucleic acid molecule comprising SEQ ID NO:38.

43. A kit for detecting the presence of the expression of a tumor associated polypeptide precursor comprising a first isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of SEQ ID NO:43, and a second isolated nucleic acid molecule consisting of a 12-32 nucleotide contiguous segment of the complement of SEQ ID NO:43, wherein the contiguous segments are nonoverlapping.

44. The kit of claim 43, wherein the first and the second isolated nucleic acid molecules are constructed and arranged to selectively amplify at least a portion of an isolated nucleic acid molecule comprising SEQ ID NO:43.

45. A method for treating a subject with a disorder characterized by expression of a tumor associated nucleic acid as claimed in claim 1, comprising

administering to the subject an amount of an agent, which enriches selectively in the subject the presence of complexes of an HLA molecule and a polypeptide encoded by the tumor associated nucleic acid as claimed in claim 1, effective to ameliorate the disorder.

46. The method of claim 45, wherein the disorder is cancer.

47. A method for treating a subject having a condition characterized by expression of a tumor associated antigen encoded by a tumor associated nucleic acid as claimed in claim 1 in cells of the subject, comprising:

- (i) removing an immunoreactive cell containing sample from the subject,
- (ii) contacting the immunoreactive cell containing sample to a host cell under conditions favoring production of cytolytic T cells against the tumor associated antigen which is a fragment of the precursor,
- (iii) introducing the cytolytic T cells to the subject in an amount effective to lyse cells which express the tumor associated antigen, wherein the host cell is transformed or transfected with an expression vector comprising the isolated nucleic acid molecule of claim 1 operably linked to a promoter.

48. The method of claim 47, wherein the host cell recombinantly expresses an HLA molecule which binds the tumor associated antigen.

49. The method of claim 47, wherein the host cell endogenously expresses an HLA molecule which binds the tumor associated antigen.

50. A method for producing a tumor associated polypeptide comprising  
providing a nucleic acid molecule comprising a tumor associated nucleic acid  
molecule operably linked to a promoter, wherein the tumor associated nucleic acid molecule  
encodes the tumor associated polypeptide or a fragment thereof, wherein the tumor associated  
polypeptide is selected from the group consisting of SEQ ID NO:39, SEQ ID NO:44, and  
fragments thereof  
expressing the nucleic acid molecule in an expression system, and  
isolating the tumor associated polypeptide or a fragment thereof from the expression  
system.

## 5

10

**Express Mail Label No.:**  
**EL056827835US**  
**Date of Deposit: 10/30/98**

Attorney's Docket No. **L0461/7047**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Martelange et al.  
Serial No. : Unknown  
Filing Date : Herewith  
For : TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR


---

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

STATEMENT PURSUANT TO 37 CFR 1.821(f)

This statement is made pursuant to 37 CFR 1.821(f). Applicants enclose herewith an original copy of the Sequence Listing and a computer readable diskette. Applicants' agent states that the content of the paper copy of the Sequence Listing and the computer readable diskette contain the identical information and contain no new matter.

Respectfully submitted,



John R. Van Amsterdam  
Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Tel. (617) 720-3500

ATTORNEY DOCKET NO. L0461/7047  
Date: October 30, 1998  
**xndd**

- 1 -

SEQUENCE LISTING

5 <110> Martelange, Valérie  
De Smet, Charles  
Boon-Falleur, Thierry

<120> TUMOR ASSOCIATED NUCLEIC ACIDS AND USES THEREFOR

10 <130> L0461/7047

<150> 09/060,706  
<151> 1999-04-15

15 <160> 44

<210> 1  
<211> 204  
<212> DNA  
<213> Homo sapiens

20 <400> 1  
gatcgttgta cctcttcaag caaaatgaaa attctttcat aattttgcc aaaccttoga 60  
acttctttca ttaattgata tttatatca tcattaattt tctttgccat ggcaggagat 120  
25 atttgtggtg tatttggcac agtttcaccg aagacattac tgtaactggt gggtcacgtg 180  
cagagacact gtagtttttg gtgc 204

<210> 2  
<211> 20  
<212> DNA  
<213> Homo sapiens

30 <400> 2  
35 tgtacctctt caagcaaaat 20

<210> 3  
<211> 20  
<212> DNA  
<213> Homo sapiens

40 <400> 3  
gtgaccaccc agttacagta 20

45 <210> 4  
<211> 9  
<212> PRT  
<213> Homo sapiens

50 <400> 4  
Glu Ala Asp Pro Thr Gly His Ser Tyr  
1 5

5  
 <210> 5  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 5

10 Ser Ala Tyr Gly Glu Pro Arg Lys Leu  
 1 5

15  
 <210> 6  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 6

20 Glu Val Asp Pro Ile Gly His Leu Tyr  
 1 5

25  
 <210> 7  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 7

30 Phe Leu Trp Gly Pro Arg Ala Leu Val  
 1 5

35  
 <210> 8  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

<400> 8

40 Met Glu Val Asp Pro Ile Gly His Leu Tyr  
 1 5 10

45  
 <210> 9  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 9

50 Ala Ala Arg Ala Val Phe Leu Ala Leu  
 1 5

<210> 10  
 <211> 8  
 <212> PRT  
 <213> Homo sapiens

5

<400> 10

Tyr Arg Pro Arg Pro Arg Arg Tyr  
 1 5

10

<210> 11  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

15

<400> 11

Ser Pro Ser Ser Asn Arg Ile Arg Asn Thr  
 1 5 10

20

<210> 12  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

25

<400> 12

Val Leu Pro Asp Val Phe Ile Arg Cys  
 1 5

30

<210> 13  
 <211> 10  
 <212> PRT  
 <213> Homo sapiens

35

<400> 13

Val Leu Pro Asp Val Phe Ile Arg Cys Val  
 1 5 10

40

<210> 14  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

45

<400> 14

Glu Glu Lys Leu Ile Val Val Leu Phe  
 1 5

50

<210> 15  
 <211> 9

<212> PRT

<213> Homo sapiens

<400> 15

5

Glu Glu Lys Leu Ser Val Val Leu Phe

1

5

<210> 16

10

<211> 10

<212> PRT

<213> Homo sapiens

<400> 16

15

Ala Cys Asp Pro His Ser Gly His Phe Val

1

5

10

<210> 17

20

<211> 10

<212> PRT

<213> Homo sapiens

<400> 17

25

Ala Arg Asp Pro His Ser Gly His Phe Val

1

5

10

<210> 18

30

<211> 9

<212> PRT

<213> Homo sapiens

<400> 18

35

Ser Tyr Leu Asp Ser Gly Ile His Phe

1

5

<210> 19

40

<211> 9

<212> PRT

<213> Homo sapiens

<400> 19

45

Ser Tyr Leu Asp Ser Gly Ile His Ser

1

5

<210> 20

50

<211> 9

<212> PRT

<213> Homo sapiens

<400> 20

Met Leu Leu Ala Val Leu Tyr Cys Leu

1

5

<210> 21

<211> 9

<212> PRT

<213> Homo sapiens

<400> 21

Tyr Met Asn Gly Thr Met Ser Gln Val

1

5

<210> 22

<211> 9

<212> PRT

<213> Homo sapiens

<400> 22

Ala Phe Leu Pro Trp His Arg Leu Phe

1

5

<210> 23

<211> 9

<212> PRT

<213> Homo sapiens

<400> 23

Ser Glu Ile Trp Arg Asp Ile Asp Phe

1

5

<210> 24

<211> 9

<212> PRT

<213> Homo sapiens

<400> 24

Tyr Glu Ile Trp Arg Asp Ile Asp Phe

1

5

<210> 25

<211> 15

<212> PRT

<213> Homo sapiens

<400> 25

Gln Asn Ile Leu Leu Ser Asn Ala Pro Leu Gly Pro Gln Phe Pro  
1 5 10 15

5 <210> 26  
<211> 15  
<212> PRT  
<213> Homo sapiens

10 <400> 26

Asp Tyr Ser Tyr Leu Gln Asp Ser Asp Pro Asp Ser Phe Gln Asp  
1 5 10 15

15 <210> 27  
<211> 10  
<212> PRT  
<213> Homo sapiens

20 <400> 27

Glu Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5 10

25 <210> 28  
<211> 9  
<212> PRT  
<213> Homo sapiens

30 <400> 28

Ala Ala Gly Ile Gly Ile Leu Thr Val  
1 5

35 <210> 29  
<211> 9  
<212> PRT  
<213> Homo sapiens

40 <400> 29

Ile Leu Thr Val Ile Leu Gly Val Leu  
1 5

45 <210> 30  
<211> 9  
<212> PRT  
<213> Homo sapiens

50 <400> 30

Lys Thr Trp Gly Gln Tyr Trp Gln Val



<210> 36  
 <211> 12  
 <212> PRT  
 <213> Homo sapiens

<400> 36

Lys Ile Ser Gly Gly Pro Arg Ile Ser Tyr Pro Leu  
 1 5 10

<210> 37  
 <211> 9  
 <212> PRT  
 <213> Homo sapiens

<400> 37

Tyr Met Asp Gly Thr Met Ser Gln Val  
 1 5

<210> 38  
 <211> 2021  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> CDS  
 <222> (119)...(1831)

<400> 38

ctcactatag ggagaccac gcttggtacc gagctoggat ccactagtaa cggcggccag 60  
 tgtgctggaa agtgttcaac cagtattat ttatttgaca gcaactggta ttccgggc 118  
 atg aat acc agg gat cag tat gct acc atc act cac aat gtc tgt gaa 166  
 Met Asn Thr Arg Asp Gln Tyr Ala Thr Ile Thr His Asn Val Cys Glu  
 1 5 10 15

gag aga gtg gta aat aac caa cca cta cct agt aac gcc ttg tca act 214  
 Glu Arg Val Val Asn Asn Gln Pro Leu Pro Ser Asn Ala Leu Ser Thr  
 20 25 30

gtt cta cca ggg ctt gct tat ttg gca aca gct gat atg cca gcc atg 262  
 Val Leu Pro Gly Leu Ala Tyr Leu Ala Thr Ala Asp Met Pro Ala Met  
 35 40 45

agt acc agg gat cag cat gct acc atc att cac aat ctg ogt gaa gag 310  
 Ser Thr Arg Asp Gln His Ala Thr Ile Ile His Asn Leu Arg Glu Glu  
 50 55 60

aag aaa gat aac agc caa cca acc cct gat aac gtc ttg tca gct gtt 358  
 Lys Lys Asp Asn Ser Gln Pro Thr Pro Asp Asn Val Leu Ser Ala Val  
 65 70 75 80

5	aca cca gag ctt att aac ttg gca gga gct ggt att cca ccc atg agt	406
	Thr Pro Glu Leu Ile Asn Leu Ala Gly Ala Gly Ile Pro Pro Met Ser 85 90 95	
10	acc agg gat cag tat gct acc gtc aat cac cat gtc cat gaa gca agg	454
	Thr Arg Asp Gln Tyr Ala Thr Val Asn His His Val His Glu Ala Arg 100 105 110	
15	atg gaa aat ggc caa cga aaa cag gat aac gtc ttg tca aat gtt cta	502
	Met Glu Asn Gly Gln Arg Lys Gln Asp Asn Val Leu Ser Asn Val Leu 115 120 125	
20	tcc ggg ctt att aat atg gca gga gct agt att cca gca atg agt tcc	550
	Ser Gly Leu Ile Asn Met Ala Gly Ala Ser Ile Pro Ala Met Ser Ser 130 135 140	
25	agg gat ctg tat gct acc att act cac agt gtt cgt gaa gag aag atg	598
	Arg Asp Leu Tyr Ala Thr Ile Thr His Ser Val Arg Glu Glu Lys Met 145 150 155 160	
30	gaa agt ggc aaa ccc cag act gat aag gtc ata tca aat gat gca cca	646
	Glu Ser Gly Lys Pro Gln Thr Asp Lys Val Ile Ser Asn Asp Ala Pro 165 170 175	
35	cag ctt ggt cat atg gct gca ggt ggt att cca tcc atg agt acc aag	694
	Gln Leu Gly His Met Ala Ala Gly Gly Ile Pro Ser Met Ser Thr Lys 180 185 190	
40	gat ctg tat gct acc gtc act caa aat gtc cat gaa gag agg atg gaa	742
	Asp Leu Tyr Ala Thr Val Thr Gln Asn Val His Glu Glu Arg Met Glu 195 200 205	
45	aat aac caa cca caa cct agt tat gac ttg tca act gtt cta cca gga	790
	Asn Asn Gln Pro Gln Pro Ser Tyr Asp Leu Ser Thr Val Leu Pro Gly 210 215 220	
50	ctt act tat ttg aca gta gct ggt att cgg gcc atg agt acc agg gat	838
	Leu Thr Tyr Leu Thr Val Ala Gly Ile Pro Ala Met Ser Thr Arg Asp 225 230 235 240	
55	cag tat gct acc gtc act cac aat gtc cat gaa gag aag att aaa aat	886
	Gln Tyr Ala Thr Val Thr His Asn Val His Glu Glu Lys Ile Lys Asn 245 250 255	
60	ggc caa gca gca tcc gat aat gtc ttc tog act gtt cca cca gca ttt	934
	Gly Gln Ala Ala Ser Asp Asn Val Phe Ser Thr Val Pro Ala Phe 260 265 270	
65	att aat atg gca gca act ggt gtt tca tcc atg agt acc agg gat cag	982
	Ile Asn Met Ala Ala Thr Gly Val Ser Ser Met Ser Thr Arg Asp Gln 275 280 285	

tat gct gca gtc act cac aac atc cgt gaa gag aag ata aat aac agc 1030  
Tyr Ala Ala Val Thr His Asn Ile Arg Glu Glu Lys Ile Asn Asn Ser  
290 295 300

caa cca gca cct ggt aac atc ttg tca act gct cct cca tgg ctt cgt 1078  
Gln Pro Ala Pro Gly Asn Ile Leu Ser Thr Ala Pro Pro Trp Leu Arg  
305 310 315 320

cat atg gca gca gct gga att tca tcc acg att acc agg gat ctg tat 1126  
His Met Ala Ala Ala Gly Ile Ser Ser Thr Ile Thr Arg Asp Leu Tyr  
325 330 335

gtc acc gcc act cac agt gtc cat gag gag aag atg aca aat ggc caa 1174  
Val Thr Ala Thr His Ser Val His Glu Glu Lys Met Thr Asn Gly Gln  
340 345 350

cag gca cct gat aac tcc ttg tca acg gtt cca cct ggt tgt att aat 1222  
Gln Ala Pro Asp Asn Ser Leu Ser Thr Val Pro Pro Gly Cys Ile Asn  
355 360 365

ctg tca gga gct ggt att tca tgc aga agt acc agg gat ctg tat gct 1270  
Leu Ser Gly Ala Gly Ile Ser Cys Arg Ser Thr Arg Asp Leu Tyr Ala  
370 375 380

act gtc att cac gat atc cag gag gag gag atg gaa aat gat caa acc 1318  
Thr Val Ile His Asp Ile Gln Glu Glu Glu Met Glu Asn Asp Gln Thr  
385 390 395 400

cct cct gat ggc ttc ctg tca aat tct gat tca cca gag ctg ata aat 1366  
Pro Pro Asp Gly Phe Leu Ser Asn Ser Asp Ser Pro Glu Leu Ile Asn  
405 410 415

atg aca gga cat tgt atg cca ccc aat gca ttg gat tct ttc tct cac 1414  
Met Thr Gly His Cys Met Pro Pro Asn Ala Leu Asp Ser Phe Ser His  
420 425 430

gac ttc aca agt ctc agc aaa gat gag ctg ctt tac aaa cct gat agt 1462  
Asp Phe Thr Ser Leu Ser Lys Asp Glu Leu Leu Tyr Lys Pro Asp Ser  
435 440 445

aat gaa ttt gcg gta ggc acc aaa aac tac agt gtc tct gca ggt gac 1510  
Asn Glu Phe Ala Val Gly Thr Lys Asn Tyr Ser Val Ser Ala Gly Asp  
450 455 460

cca cca gtt aca gta atg tct tgg gtg gaa act gtg cca aat aca cca 1558  
Pro Pro Val Thr Val Met Ser Ser Val Glu Thr Val Pro Asn Thr Pro  
465 470 475 480

caa ata tct cct gcc atg gca aaa aaa att aat gat gat ata aaa tat 1606  
Gln Ile Ser Pro Ala Met Ala Lys Lys Ile Asn Asp Asp Ile Lys Tyr  
485 490 495

caa tta atg aaa gaa gtt oga agg ttt ggg caa aat tat gaa aga att 1654  
Gln Leu Met Lys Glu Val Arg Phe Gly Gln Asn Tyr Glu Arg Ile  
500 505 510

5 ttc att ttg ctt gaa gag gta caa gga tct atg aaa gtc aag aga caa 1702  
Phe Ile Leu Leu Glu Glu Val Gln Gly Ser Met Lys Val Lys Arg Gln  
515 520 525

10 ttt gtt gaa ttt acc atc aag gaa gca gca agg ttt aaa aaa gtt gtc 1750  
Phe Val Glu Phe Thr Ile Lys Glu Ala Ala Arg Phe Lys Lys Val Val  
530 535 540

15 tta att cag caa ctc gag aag gog ctt aaa gaa ata gat tcc cac tgc 1798  
Leu Ile Gln Gln Leu Glu Lys Ala Leu Lys Glu Ile Asp Ser His Cys  
545 550 555 560

cat ctc aga aaa gtt aag cac atg aga aaa aga taattgtgtt agtgcaaga 1851  
His Leu Arg Lys Val Lys His Met Arg Lys Arg  
565 570

ccaaggagaaa acaaggacat atgctgtagg atggaacagg ttattgtctga agctccctat 1911  
aatcctgaaa tgaagagaat tcccttcag aagctacgaa aaagggagct gtttaaattt 1971  
aataaatctc tggtagtaaa agctgcaaaa aaaaaaaaaa aaaaaaaaaa 2021

<210> 39  
<211> 571  
<212> PRT  
<213> H. sapiens

<400> 39  
Met Asn Thr Arg Asp Gln Tyr Ala Thr Ile Thr His Asn Val Cys Glu  
1 5 10 15  
Glu Arg Val Val Asn Asn Gln Pro Leu Pro Ser Asn Ala Leu Ser Thr  
20 25 30  
Val Leu Pro Gly Leu Ala Tyr Leu Ala Thr Ala Asp Met Pro Ala Met  
35 40 45  
Ser Thr Arg Asp Gln His Ala Thr Ile Ile His Asn Leu Arg Glu Glu  
50 55 60  
Lys Lys Asp Asn Ser Gln Pro Thr Pro Asp Asn Val Leu Ser Ala Val  
65 70 75 80  
Thr Pro Glu Leu Ile Asn Leu Ala Gly Ala Gly Ile Pro Pro Met Ser  
85 90 95  
Thr Arg Asp Gln Tyr Ala Thr Val Asn His His Val His Glu Ala Arg  
100 105 110  
Met Glu Asn Gly Gln Arg Lys Gln Asp Asn Val Leu Ser Asn Val Leu  
115 120 125  
Ser Gly Leu Ile Asn Met Ala Gly Ala Ser Ile Pro Ala Met Ser Ser  
130 135 140  
Arg Asp Leu Tyr Ala Thr Ile Thr His Ser Val Arg Glu Glu Lys Met  
145 150 155 160  
Glu Ser Gly Lys Pro Gln Thr Asp Lys Val Ile Ser Asn Asp Ala Pro

165 170 175  
 Gln Leu Gly His Met Ala Ala Gly Gly Ile Pro Ser Met Ser Thr Lys  
 180 185 190  
 5 Asp Leu Tyr Ala Thr Val Thr Gln Asn Val His Glu Glu Arg Met Glu  
 195 200 205  
 Asn Asn Gln Pro Gln Pro Ser Tyr Asp Leu Ser Thr Val Leu Pro Gly  
 210 215 220  
 Leu Thr Tyr Leu Thr Val Ala Gly Ile Pro Ala Met Ser Thr Arg Asp  
 225 230 235 240  
 10 Gln Tyr Ala Thr Val Thr His Asn Val His Glu Glu Lys Ile Lys Asn  
 245 250 255  
 Gly Gln Ala Ala Ser Asp Asn Val Phe Ser Thr Val Pro Pro Ala Phe  
 260 265 270  
 Ile Asn Met Ala Ala Thr Gly Val Ser Ser Met Ser Thr Arg Asp Gln  
 275 280 285  
 15 Tyr Ala Ala Val Thr His Asn Ile Arg Glu Glu Lys Ile Asn Asn Ser  
 290 295 300  
 Gln Pro Ala Pro Gly Asn Ile Leu Ser Thr Ala Pro Pro Trp Leu Arg  
 305 310 315 320  
 20 His Met Ala Ala Ala Gly Ile Ser Ser Thr Ile Thr Arg Asp Leu Tyr  
 325 330 335  
 Val Thr Ala Thr His Ser Val His Glu Glu Lys Met Thr Asn Gly Gln  
 340 345 350  
 Gln Ala Pro Asp Asn Ser Leu Ser Thr Val Pro Pro Gly Cys Ile Asn  
 355 360 365  
 25 Leu Ser Gly Ala Gly Ile Ser Cys Arg Ser Thr Arg Asp Leu Tyr Ala  
 370 375 380  
 Thr Val Ile His Asp Ile Gln Glu Glu Met Glu Asn Asp Gln Thr  
 385 390 395 400  
 30 Pro Pro Asp Gly Phe Leu Ser Asn Ser Asp Ser Pro Glu Leu Ile Asn  
 405 410 415  
 Met Thr Gly His Cys Met Pro Pro Asn Ala Leu Asp Ser Phe Ser His  
 420 425 430  
 35 Asp Phe Thr Ser Leu Ser Lys Asp Glu Leu Leu Tyr Lys Pro Asp Ser  
 435 440 445  
 Asn Glu Phe Ala Val Gly Thr Lys Asn Tyr Ser Val Ser Ala Gly Asp  
 450 455 460  
 Pro Pro Val Thr Val Met Ser Ser Val Glu Thr Val Pro Asn Thr Pro  
 465 470 475 480  
 40 Gln Ile Ser Pro Ala Met Ala Lys Lys Ile Asn Asp Asp Ile Lys Tyr  
 485 490 495  
 Gln Leu Met Lys Glu Val Arg Arg Phe Gly Gln Asn Tyr Glu Arg Ile  
 500 505 510  
 45 Phe Ile Leu Leu Glu Glu Val Gln Gly Ser Met Lys Val Lys Arg Gln  
 515 520 525  
 Phe Val Glu Phe Thr Ile Lys Glu Ala Ala Arg Phe Lys Lys Val Val  
 530 535 540  
 Leu Ile Gln Gln Leu Glu Lys Ala Leu Lys Glu Ile Asp Ser His Cys  
 545 550 555 560  
 50 His Leu Arg Lys Val Lys His Met Arg Lys Arg  
 565 570

<210> 40  
 <211> 201  
 <212> DNA  
 <213> H. sapiens

5  
 <400> 40  
 gatctccctg aacctctact tacttttgaa tattacgaat tatttgtaaa cattttgggc 60  
 ttgctgcaac ctcatttaga gaggggtgcc atcgatgctc tacagttatg ttgtttgtta 120  
 cttcccccac caaatogtag aaagettcaa cttttaatgc gtatgatttc cogaatgagt 180  
 10 caaaatgttg atatgcccaa a 201

<210> 41  
 <211>  
 <212> DNA  
 <213> H. sapiens

15  
 <400> 41  
 tctccctgaa cctctactta 20

<210> 42  
 <211>  
 <212> DNA  
 <213> H. sapiens

20  
 <400> 42  
 atatcaacat tttgactcat 20

<210> 43  
 <211> 2463  
 <212> DNA  
 <213> H. sapiens

<220>  
 <221> CDS  
 <222> (79) ... (1659)

35  
 <400> 43  
 gcttggtacc gagctggat ccactagtaa cggcggccag tgtgctggaa agggagccaa 60  
 cggggcgctg acagacct atg gag agt cag ggt gtg cct ccc ggg cct tat 111  
 Met Glu Ser Gln Gly Val Pro Pro Gly Pro Tyr  
 1 5 10

40  
 cgg gcc acc aag ctg tgg aat gaa gtt acc aca tct ttt cga gca gga 159  
 Arg Ala Thr Lys Leu Trp Asn Glu Val Thr Thr Ser Phe Arg Ala Gly  
 15 20 25

45  
 atg cct cta aga aaa cac aga caa cac ttt aaa aaa tat ggc aat tgt 207  
 Met Pro Leu Arg Lys His Arg Gln His Phe Lys Lys Tyr Gly Asn Cys  
 30 35 40

50  
 ttc aca gca gga gaa gca gtg gat tgg ctt tat gac cta tta aga aat 255  
 Phe Thr Ala Gly Glu Ala Val Asp Trp Leu Tyr Asp Leu Leu Arg Asn

	45	50	55	
	aat agc aat ttt ggt cct gaa gtt aca agg caa cag act atc caa ctg			303
	Asn Ser Asn Phe Gly Pro Glu Val Thr Arg Gln Gln Thr Ile Gln Leu			
5	60	65	70	75
	ttg agg aaa ttt ctt aag aat cat gta att gaa gat atc aaa ggg agg			351
	Leu Arg Lys Phe Leu Lys Asn His Val Ile Glu Asp Ile Lys Gly Arg			
		80	85	90
10	tgg gga tca gaa aat gtt gat gat aac aac cag ctc ttc aga ttt cct			399
	Trp Gly Ser Glu Asn Val Asp Asp Asn Asn Gln Leu Phe Arg Phe Pro			
		95	100	105
15	gca act tgg cca ctt aaa act cta cca cga agg tat cca gaa ttg aga			447
	Ala Thr Ser Pro Leu Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu Arg			
		110	115	120
	aaa aac aac ata gag aac ttt tcc aaa gat aaa gat agc att ttt aaa			495
20	Lys Asn Asn Ile Glu Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe Lys			
		125	130	135
	tta cga aac tta tct cgt aga act cct aaa agg cat gga tta cat tta			543
	Leu Arg Asn Leu Ser Arg Arg Thr Pro Lys Arg His Gly Leu His Leu			
25	140	145	150	155
	tct cag gaa aat ggc gag aaa ata aag cat gaa ata atc aat gaa gat			591
	Ser Gln Glu Asn Gly Glu Lys Ile Lys His Glu Ile Ile Asn Glu Asp			
		160	165	170
30	caa gaa aat gca att gat aat aga gaa cta agc cag gaa gat gtt gaa			639
	Gln Glu Asn Ala Ile Asp Asn Arg Glu Leu Ser Gln Glu Asp Val Glu			
		175	180	185
35	gaa gtt tgg aga tat gtt att ctg atc tac ctg caa acc att tta ggt			687
	Glu Val Trp Arg Tyr Val Ile Leu Ile Tyr Leu Gln Thr Ile Leu Gly			
		190	195	200
40	gtg cca tcc cta gaa gaa gtc ata aat cca aaa caa gta att ccc caa			735
	Val Pro Ser Leu Glu Glu Val Ile Asn Pro Lys Gln Val Ile Pro Gln			
		205	210	215
	tat ata atg tac aac atg gcc aat aca agt aaa cgt gga gta gtt ata			783
	Tyr Ile Met Tyr Asn Met Ala Asn Thr Ser Lys Arg Gly Val Val Ile			
45	220	225	230	235
	cta caa aac aaa tca gat gac ctc cct cac tgg gta tta tct gcc atg			831
	Leu Gln Asn Lys Ser Asp Asp Leu Pro His Trp Val Leu Ser Ala Met			
		240	245	250
50	aag tgc cta goa aat tgg cca aga agc aat gat atg aat aat cca act			879
	Lys Cys Leu Ala Asn Trp Pro Arg Ser Asn Asp Met Asn Asn Pro Thr			

	255	260	265	
	tat gtt gga ttt gaa cga gat gta ttc aga aca atc gca gat tat ttt	927		
5	Tyr Val Gly Phe Glu Arg Asp Val Phe Arg Thr Ile Ala Asp Tyr Phe			
	270 275 280			
	cta gat ctc cct gaa cct cta ctt act ttt gaa tat tac gaa tta ttt	975		
	Leu Asp Leu Pro Glu Pro Leu Leu Thr Phe Glu Tyr Tyr Glu Leu Phe			
	285 290 295			
10	gta aac att ttg ggc ttg ctg caa cct cat tta gag agg gtt gcc atc	1023		
	Val Asn Ile Leu Gly Leu Leu Gln Pro His Leu Glu Arg Val Ala Ile			
	300 305 310 315			
15	gat gct cta cag tta tgt tgt ttg tta ctt ccc cca cca aat cgt aga	1071		
	Asp Ala Leu Gln Leu Cys Cys Leu Leu Leu Pro Pro Pro Asn Arg Arg			
	320 325 330			
	aag ctt caa ctt tta atg cgt atg att tcc cga atg agt caa aat gtt	1119		
20	Lys Leu Gln Leu Leu Met Arg Met Ile Ser Arg Met Ser Gln Asn Val			
	335 340 345			
	gat atg ccc aaa ctt cat gat gca atg ggt acg agg tca ctg atg ata	1167		
	Asp Met Pro Lys Leu His Asp Ala Met Gly Thr Arg Ser Leu Met Ile			
25	350 355 360			
	cat acc ttt tct cga tgt gtg tta tgc tgt gct gaa gaa gtg gat ctt	1215		
	His Thr Phe Ser Arg Cys Val Leu Cys Cys Ala Glu Glu Val Asp Leu			
	365 370 375			
30	gat gag ctt ctt gct gga aga tta gtt tct ttc tta atg gat cat cat	1263		
	Asp Glu Leu Leu Ala Gly Arg Leu Val Ser Phe Leu Met Asp His His			
	380 385 390 395			
35	cag gaa att ctt caa gta ccc tct tac tta cag act gca gtg gaa aaa	1311		
	Gln Glu Ile Leu Gln Val Pro Ser Tyr Leu Gln Thr Ala Val Glu Lys			
	400 405 410			
40	cat ctt gac tac tta aaa aag gga cat att gaa aat cct gga gat gga	1359		
	His Leu Asp Tyr Leu Lys Lys Gly His Ile Glu Asn Pro Gly Asp Gly			
	415 420 425			
45	cta ttt gct cct ttg cca act tac tca tac tgt aag cag att agt gct	1407		
	Leu Phe Ala Pro Leu Pro Thr Tyr Ser Tyr Cys Lys Gln Ile Ser Ala			
	430 435 440			
	cag gag ttt gat gag caa aaa gtt tct acc tct caa gct gca att gca	1455		
	Gln Glu Phe Asp Glu Gln Lys Val Ser Thr Ser Gln Ala Ala Ile Ala			
	445 450 455			
50	gaa ctt tta gaa aat att att aaa aac agg agt tta cct cta aag gag	1503		
	Glu Leu Leu Glu Asn Ile Ile Lys Asn Arg Ser Leu Pro Leu Lys Glu			

	460	465	470	475	
	aaa aga aaa aaa cta aaa cag ttt cag aag gaa tat cct ttg ata tat				1551
5	Lys Arg Lys Lys Leu Lys Gln Phe Gln Lys Glu Tyr Pro Leu Ile Tyr	480	485	490	
	cag aaa aga ttt cca acc acg gag agt gaa gca gca ctt ttt ggt gac				1599
	Gln Lys Arg Phe Pro Thr Thr Glu Ser Glu Ala Ala Leu Phe Gly Asp	495	500	505	
10	aaa cct aca atc aag caa cca atg ctg att tta aga aaa cca aag ttc				1647
	Lys Pro Thr Ile Lys Gln Pro Met Leu Ile Leu Arg Lys Pro Lys Phe	510	515	520	
15	cgt agt cta aga taactaactg aattaaaaat tatgtaatac ttgtggaact				1699
	Arg Ser Leu Arg	525			
20	ttgataaatg aagccatatac tgagaatgta gctactcaaa aggaagtctg tcattaataa				1759
	ggatatttcta aataaacaca ttatgtaagg aagtgccaaa atagttatca atgtgagact				1819
	cttaggaaac taactagatc tcaattgaga gcacataaca atagatgata ccaataactt				1879
	tttgttttta acacagctat ccagtaaggc tatcatgatg tgtgctaaaa ttttatttac				1939
	ttgaattttg aaaactgagc tgtgttaggg attaaactat aattctgttc ttaaaagaaa				1999
	atttatctgc aaatgtgcaa gttctgagat attagctaag gaattagttg tttggggtta				2059
25	cttctttgtt tctaagtata agaattgtgaa gaattttga aaactcaatg aaataattct				2119
	cagctgccaa atgttgcaact cttttatata ttctttttcc acttttgatc tatttatata				2179
	tatgtatgtg tttttaaaat atgtgtatat ttatcagat ttggtttgc cttaaatatt				2239
	atcccaatt gcttcagtc ttcattttgt cagtatatat attttgaatt ctagttttca				2299
	taatctatta gaagatgggg atataaaaaga agtataaggc aatcatatat tcattcaaaa				2359
30	gatatttatt tagcaactgc tatgtgcctt tegtgtgtcc agatattcag agacaatgat				2419
	aaataaaaaca tataactctc tccaaaaaaa aaaaaaaaaa aaaa				2463
	<210> 44				
	<211> 527				
35	<212> PRT				
	<213> H. sapiens				
	<400> 44				
40	Met Glu Ser Gln Gly Val Pro Pro Gly Pro Tyr Arg Ala Thr Lys Leu				
	1 5 10 15				
	Trp Asn Glu Val Thr Thr Ser Phe Arg Ala Gly Met Pro Leu Arg Lys				
	20 25 30				
	His Arg Gln His Phe Lys Lys Tyr Gly Asn Cys Phe Thr Ala Gly Glu				
	35 40 45				
45	Ala Val Asp Trp Leu Tyr Asp Leu Leu Arg Asn Asn Ser Asn Phe Gly				
	50 55 60				
	Pro Glu Val Thr Arg Gln Gln Thr Ile Gln Leu Leu Arg Lys Phe Leu				
	65 70 75 80				
	Lys Asn His Val Ile Glu Asp Ile Lys Gly Arg Trp Gly Ser Glu Asn				
50	85 90 95				
	Val Asp Asp Asn Asn Gln Leu Phe Arg Phe Pro Ala Thr Ser Pro Leu				
	100 105 110				

Lys Thr Leu Pro Arg Arg Tyr Pro Glu Leu Arg Lys Asn Asn Ile Glu  
 115 120 125  
 Asn Phe Ser Lys Asp Lys Asp Ser Ile Phe Lys Leu Arg Asn Leu Ser  
 130 135 140  
 5 Arg Arg Thr Pro Lys Arg His Gly Leu His Leu Ser Gln Glu Asn Gly  
 145 150 155 160  
 Glu Lys Ile Lys His Glu Ile Ile Asn Glu Asp Gln Glu Asn Ala Ile  
 165 170 175  
 10 Asp Asn Arg Glu Leu Ser Gln Glu Asp Val Glu Glu Val Trp Arg Tyr  
 180 185 190  
 Val Ile Leu Ile Tyr Leu Gln Thr Ile Leu Gly Val Pro Ser Leu Glu  
 195 200 205  
 Glu Val Ile Asn Pro Lys Gln Val Ile Pro Gln Tyr Ile Met Tyr Asn  
 210 215 220  
 15 Met Ala Asn Thr Ser Lys Arg Gly Val Val Ile Leu Gln Asn Lys Ser  
 225 230 235 240  
 Asp Asp Leu Pro His Trp Val Leu Ser Ala Met Lys Cys Leu Ala Asn  
 245 250 255  
 20 Trp Pro Arg Ser Asn Asp Met Asn Asn Pro Thr Tyr Val Gly Phe Glu  
 260 265 270  
 Arg Asp Val Phe Arg Thr Ile Ala Asp Tyr Phe Leu Asp Leu Pro Glu  
 275 280 285  
 Pro Leu Leu Thr Phe Glu Tyr Tyr Glu Leu Phe Val Asn Ile Leu Gly  
 290 295 300  
 25 Leu Leu Gln Pro His Leu Glu Arg Val Ala Ile Asp Ala Leu Gln Leu  
 305 310 315 320  
 Cys Cys Leu Leu Leu Pro Pro Pro Asn Arg Arg Lys Leu Gln Leu Leu  
 325 330 335  
 30 Met Arg Met Ile Ser Arg Met Ser Gln Asn Val Asp Met Pro Lys Leu  
 340 345 350  
 His Asp Ala Met Gly Thr Arg Ser Leu Met Ile His Thr Phe Ser Arg  
 355 360 365  
 Cys Val Leu Cys Cys Ala Glu Glu Val Asp Leu Asp Glu Leu Leu Ala  
 370 375 380  
 35 Gly Arg Leu Val Ser Phe Leu Met Asp His His Gln Glu Ile Leu Gln  
 385 390 395 400  
 Val Pro Ser Tyr Leu Gln Thr Ala Val Glu Lys His Leu Asp Tyr Leu  
 405 410 415  
 40 Lys Lys Gly His Ile Glu Asn Pro Gly Asp Gly Leu Phe Ala Pro Leu  
 420 425 430  
 Pro Thr Tyr Ser Tyr Cys Lys Gln Ile Ser Ala Gln Glu Phe Asp Glu  
 435 440 445  
 Gln Lys Val Ser Thr Ser Gln Ala Ala Ile Ala Glu Leu Leu Glu Asn  
 450 455 460  
 45 Ile Ile Lys Asn Arg Ser Leu Pro Leu Lys Glu Lys Arg Lys Lys Leu  
 465 470 475 480  
 Lys Gln Phe Gln Lys Glu Tyr Pro Leu Ile Tyr Gln Lys Arg Phe Pro  
 485 490 495  
 50 Thr Thr Glu Ser Glu Ala Ala Leu Phe Gly Asp Lys Pro Thr Ile Lys  
 500 505 510  
 Gln Pro Met Leu Ile Leu Arg Lys Pro Lys Phe Arg Ser Leu Arg  
 515 520 525

00103700.100000